Throughout this Annual Report, you will find pictures of some of our family members, each of whom represents thousands of others, all working in different ways to make the Society’s goals a reality.
The Leukemia & Lymphoma Society is a family of volunteers, researchers and staff, dedicated to advancing a common mission:

To cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and to improve the quality of life of patients and their families.
Our family has a very personal reason for caring about finding cures for blood cancers. We lost a child to leukemia, and nothing can ever compensate for that loss. It is our wish that other families be spared that pain.

Over more than 20 years, I’ve seen the Society make strides toward a day when our wish becomes reality. Through Society-sponsored research, less toxic, targeted treatments are being discovered that save, prolong and enhance the lives of patients and their families. Every year, through Society programs, more and more patients are being reached with the information and support they need to survive blood cancers. And every year, more patients survive. But not all. Sadly, in the United States alone, we expect blood cancers to cause the deaths of more than 58,000 people this year.

I am proud to lend my name to the Society and its work. Because of the efforts of its volunteers, staff and medical and research partners, we are closer than ever to cures for leukemia, lymphoma, Hodgkin’s disease and myeloma. And I have faith that continued support for their efforts is the key to realizing those cures.

Barbara Bush
National Honorary Chair
Advancing our Mission

In Fiscal Year 2002, the Society faced the severe new challenges issued by global uncertainty and economic upheaval. In a suddenly changed environment, our volunteers and staff responded by working even harder and in closer partnership, making creative use of every resource at their disposal to advance our mission. The tests they confronted required unprecedented teamwork, some sacrifice on every front and the benefits of earlier financial planning and technology investments. But at the end of the year the Society emerged stronger than before. Revenues rose slightly to an all-time high of $151.5 million, and our ability to serve and support the people who rely on us was uncompromised.

The Society funded $37.6 million in blood cancer research this year — a $1.5 million increase over Fiscal Year 2001 — underscoring our commitment to mission. Investments in research brought the wonderful dividend of less toxic, more life-enhancing and life-prolonging treatments for patients.

Our Specialized Center of Research (SCOR) Program welcomed a new team at the Fred Hutchinson Cancer Research Center in Seattle. There, Irwin Bernstein, M.D., leads a group of investigators studying the Immunotherapy of Hematological Malignancies, arming immune cells or antibodies with toxic agents to kill cancer cells without affecting normal ones. These approaches, if successful, will offer hope to thousands of blood cancer patients, whose inability to tolerate non-targeted toxic therapies often leaves them without access to the most effective means of combating their diseases.

The Society made significant strides toward our long-term goal of reaching all newly-diagnosed blood cancer patients, and making our services available to each of them. This year we responded to more than 200,000 requests for assistance through our Information Resource Center (IRC), patient outreach programs in our chapters across the country and our Web site.

Chapter and electronic resources helped us more than double — to 7,500 — the number of advocacy volunteers who work for our organization. On April 30, we attended a “lobby day” in Washington D.C. as part of The Blood Cancer Coalition, and celebrated congressional passage of the Hematological Cancer Research and Education Investment Act that very day.

We would like to express our tremendous gratitude to the members of our board, our volunteers, donors and staff for their resilience and ability to move forward through the winds of change, and persevere. As a result of our teamwork, we’re able to look back on 2002 with a sense of accomplishment at our progress toward cures for blood cancers, and improved quality of life for patients and their families.

Norbert J. Sieber
Chairman

Dwayne Howell
President & CEO
LEUKEMIA

• A malignant disease of the bone marrow and blood

• Common types of leukemia are divided into four categories: myelogenous or lymphocytic, which can be acute or chronic

• Approximately 30,800 new cases of leukemia will be diagnosed in the United States this year

• Leukemia strikes 10 times as many adults as children

• It remains the leading cause of disease-related deaths among children under age 15

• Approximately 21,700 Americans will die from leukemia this year

• The five-year survival rate for children under age 15 with acute lymphocytic leukemia (ALL) is now 85 percent

• The five-year relative survival rate for leukemia is 46 percent

Note: Relative survival rate refers to an estimated percent of patients that would be expected to survive the effects of their cancer.

“We run support groups for inner city teens with blood cancers. We’re more than their doctors – we’re their counselors and confidantes. It’s a thrill to make a difference in these kids’ lives.”

DR. SADANANDAN is CHIEF OF PEDIATRIC HEMATOLOGY AND ONCOLOGY AT BROOKLYN HOSPITAL IN NEW YORK CITY.
Every day, in the United States alone, more than 300 people learn they have blood cancer. Every nine minutes, someone dies.

<table>
<thead>
<tr>
<th>L Y M P H O M A</th>
<th>M Y E L O M A</th>
</tr>
</thead>
<tbody>
<tr>
<td>• A group of cancers that originates in the lymphatic system</td>
<td>• A cancer of the plasma cells, a type of white blood cell found mainly in bone marrow</td>
</tr>
<tr>
<td>• The two main types of lymphoma are non-Hodgkin and Hodgkin lymphoma (also called Hodgkin’s disease)</td>
<td>• Its cause is unknown and it is the most intractable of the blood cancers with survival at only 30 percent</td>
</tr>
<tr>
<td>• Approximately 60,900 new lymphoma cases will be diagnosed in the United States this year</td>
<td>• Approximately 14,600 new myeloma cases will be diagnosed in the United States this year</td>
</tr>
<tr>
<td>• The relative survival rate for patients under age 20 with Hodgkin lymphoma is 93 percent</td>
<td>• Eighty percent of myeloma cases occur after age 60; it is rarely found in individuals under age 50</td>
</tr>
<tr>
<td>• In children with non-Hodgkin lymphoma, the five-year survival rate is 78 percent</td>
<td>• Incidence rates for myeloma are approximately 50 percent higher in men than in women and twice as high for African Americans than for all other races</td>
</tr>
<tr>
<td>• Approximately 25,800 Americans will die from lymphoma this year</td>
<td>• Approximately 10,800 Americans will die from myeloma this year</td>
</tr>
<tr>
<td>• Hodgkin lymphoma is one of the most curable cancers; the five-year relative survival rate is now 85 percent</td>
<td></td>
</tr>
<tr>
<td>• The five-year relative survival rate for non-Hodgkin lymphoma is now 55 percent</td>
<td></td>
</tr>
</tbody>
</table>

The Society is structured for synergy, supporting research and patient services for all major blood cancers.
“As director of the Society Specialized Center of Research for Multiple Myeloma, I coordinate four synergistic teams to investigate the development and control of myeloma. We expect this to lead to new and better therapies for myeloma patients.”

Selina Chen-Kiang, Ph.D.,
Society-funded Researcher, Weill Medical College of Cornell University, New York, NY
Discovering cures through leading-edge research

This year, we continued full speed ahead with advances toward cures. We supported scientists at the forefront of blood cancer research around the world through our Career Development Program, Translational Research Programs and Specialized Center of Research (SCOR) Program, now in its third year.

The Leukemia & Lymphoma Society is structured to provide high potential for superior returns on our cancer research investment. This advantage stems from the scope, magnitude and focus of our funding. Our researchers work across all blood cancers, at levels of funding that create economies of scale. As a nonprofit organization, we fill the void created by government and corporate-funded research by awarding grants to projects with higher risk/reward profiles.

Society sponsored research on leukemia, lymphoma and myeloma this year ranged from basic genomics (gene structure and function analysis) to studies utilizing advanced technologies like DNA microarray chips to diagnose illness and seek cures. Much of the research we support focuses on turning hard science into life-enhancing treatments that increase survival rates and enhance the quality of life of patients and families.

This year, 23 new Translational Research awards were granted and six renewals were made for programs approaching clinical trial stages. Seventy-four new awards went to researchers in our Career Development Program.

$37.6 million was granted to 481 individual researchers or projects in 15 countries on five continents in 2002.
Making important progress

**In 2002, therapeutic advances were made on all disease fronts ...**

**Leukemia** — In May, Gleevec™, the breakthrough therapy that kills cancer cells without harming normal ones, was shown to be superior to standard therapies used to treat chronic myelogenous leukemia (CML) patients. Brian Druker, M.D. pioneered the successful application of Gleevec to a smaller group of CML patients who were resistant to other therapies. Along with his Specialized Center of Research team, Dr. Druker is now performing clinical trials of Gleevec in combination with other chemotherapeutic agents to see whether patients can achieve a long-term remission.

Two clinical trials for patients with acute myelogenous leukemia (AML) are being conducted by Society researchers. One is headed by James Griffin, M.D., of the Dana-Farber Cancer Institute and the other by Donald Small, M.D., Ph.D., of The Johns Hopkins University. These trials use new molecularly-targeted drugs that inhibit the growth-signaling molecule, FLT-3. These new therapies may help limit the growth of AML cells without harming normal cells. If so, these drugs could add to the arsenal of more effective, less toxic ways to fight leukemia.

**Myeloma** — Robert Orlowski, M.D., Ph.D. is testing a new class of cancer-fighting drugs called proteasome inhibitors. One of these, currently in clinical trials, is PS-341. This drug blocks the breakdown of proteins — a group of large molecules that carry out most of the cell’s functions and are the building blocks of the cell. Myeloma cells appear to be particularly sensitive to this drug. Patients are responding with reduced numbers of cancer cells and alleviation of symptoms, including the severe bone loss and bone pain that is a hallmark of this blood cancer. Dr. Orlowski works at the University of North Carolina at Chapel Hill. He is supported by a Translational Research grant from the Society.

**Lymphoma** — Margaret Shipp, M.D. has found a gene that predicts the aggressiveness of diffuse B cell lymphomas. Her research may allow early identification of the more aggressive diffuse lymphomas that do not respond well to current therapies. Those patients who do not respond well to standard therapy are at higher risk for relapse but may be good candidates for early stem cell transplant or more aggressive chemotherapy. Dr. Shipp, of the Dana-Farber Cancer Institute, is supported by a Translational Research grant from the Society.
Leading the way with Specialized Centers of Research

The Society’s Specialized Center of Research (SCOR) program is a one-of-a-kind research initiative. It assembles teams of world class researchers across a range of scientific disciplines and research institutions to accelerate the discovery of breakthrough therapies for leukemia, Hodgkin and non-Hodgkin lymphoma, and myeloma. There are now seven SCORs around the world, with combined, multi-year funding totaling $52.5 million.

In 2002, a SCOR grant was awarded to Irwin Bernstein, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, WA. His team is studying ways to make effective lymphoma and leukemia therapies less toxic, making them accessible to thousands of patients who would not otherwise be able to tolerate them.

We’re winning the battle…but the war rages on.

The five-year survival rates for leukemia, lymphoma and myeloma display vastly uneven rates of improvement.

- Survival for leukemia patients has more than tripled since 1960.
- Survival for Hodgkin lymphoma has improved dramatically, yet non-Hodgkin lymphoma has not fared as well.
- Myeloma remains the most recalcitrant of blood cancers, with survival rates the least improved over the past 30 years.
Building our advocacy to affect public policy

As the need for additional resources became more critical during the year, volunteers reached out to neighbors, friends and family in Society chapters across the nation. The result: We doubled the number of grassroots advocates to more than 7,500, representing almost every congressional district in the country.

In spring 2002, the Society joined other members of The Blood Cancer Coalition to rally legislators to our cause in a “lobby day” in Washington, DC. Over two days, advocates made more than 160 congressional visits and secured scores of commitments for additional support in key areas. Among the Society’s advocates was our new International Sports Ambassador, Corina Morariu. The 1999 Wimbledon doubles champion was gearing up for a tennis comeback just one year after being diagnosed with acute promyelocytic leukemia.

Messages delivered by Society advocates to Congress increased by 250 percent this year. They took action with petitions to representatives on critical issues such as government-supported blood cancer research, Medicare coverage of oral anti-cancer drugs and funding for patient education programs.

During the year, we counted on the continued support of U.S. Sens. Kay Bailey Hutchison (R-TX) and Edward Kennedy (D-MA), and U.S. Rep. Philip M. Crane (R-IL). Our supporters also grew to include U.S. Reps. Deborah Pryce (R-OH) and Edward Schrock (R-VA), who have spearheaded efforts for blood cancer research.

Major milestones included...

- Passage of the Hematological Cancer Research and Investment Act authorizing the creation of major blood cancer research and education programs
- A new $5 million blood cancer research program at the U.S. Department of Defense
- A $1.5 million proposal to fund public and patient blood cancer education programs
Advocacy went into overdrive in 2002. With the support of volunteers all over the country, the Society’s voice for enhanced government-funded research and patient education was heard more loudly in the halls of Washington.

“Blood cancer research saved my life. I was diagnosed with acute promyelocytic leukemia in 2001. A year later, I began playing tennis again, and added my voice to those of other blood cancer advocates in Washington, D.C.”

CORINA MORARIU, WIMBLEDON DOUBLES CHAMPION AND THE SOCIETY’S INTERNATIONAL SPORTS AMBASSADOR

Ms. Morariu joined the Society and other members of the Blood Cancer Coalition at “lobby day.” Advocates visited members of Congress to build awareness of and support for issues affecting the lives of patients.
To improve the lives of patients and families...

Providing critical information and resources that prolong, enhance and save lives

The Society made significant progress toward the day when our services and support will be available to every person diagnosed with a blood cancer in the United States. Using the powerful combination of technology and human expertise, staff and volunteers made 200,000 contacts with patients and families in need of our help. These contacts were made by patient services managers at Society chapters across the country; by our Information Resource Center (IRC), where master-level professionals — social workers, nurses and health educators — responded to patient questions and concerns; and by our award-winning Web site.

- 41,000 incoming calls to our IRC…recognizing that each call is unique, and there is no formula for providing information and guidance
- Giving patients access to oncology professionals at their local chapters, through programs like Meet the Expert
- Handling 92,000 Web site visits to obtain disease information
- Offering hope to people by providing information and guidance on clinical trials through our search service, powered by HopeLink, which received 6,000 visits this year.
“When I learned I had lymphoma, someone who had been through treatment shared information no one else told me – that was invaluable. Now I’m doing the same for others.”

JOAN BAILEY, PhD, Professor, NEW JERSEY CITY UNIVERSITY, AND FIRST CONNECTION VOLUNTEER

First Connection is the Society’s community based, peer-to-peer support program for patients and survivors.

Helping where it’s needed, with community-based programs in 60 chapters

As part of our patient services programs at chapters throughout the country, we offer the guidance and support of people who best understand the needs of blood cancer patients and families — because they’ve experienced them first hand. Our First Connection program provided empathy and information on coping to more than 4,000 patients and family members this year.

NEED HELP OR KNOW SOMEONE WHO DOES? CONTACT OUR INFORMATION RESOURCE CENTER AT 800.955.4572 OR VISIT WWW.LEUKEMIA-LYMPHOMA.ORG
When blood cancer is diagnosed, treatment information can make a major difference in outcomes. The Society offers patients the opportunity to learn about the latest treatments, find out about clinical trials, ask questions of the experts and hear what others with similar concerns have to say. This knowledge arms people with the information they need to make critical decisions and go forward. A variety of programs became available in Fiscal Year 2002, covering a range of subjects, from specific disease education to issues-oriented topics such as how to cope with a blood cancer diagnosis. A few examples:

- **Myeloma: New Developments in Treatment and Research**
- **New Updates in the Treatment of Chronic Myelogenous Leukemia**, sponsored by Novartis Pharmaceuticals
- **Targeted Therapies for Lymphoma**, sponsored by IDEC
- **Cancer: Keys to Survivorship**, sponsored by Ortho Biotech.

For information on leukemia, Hodgkin and non-Hodgkin lymphoma or myeloma, call 800.955.4572 or visit www.leukemia-lymphoma.org

Society Webcasts and teleconferences are archived on our Web site for ongoing access.
Information-sharing is critical to patients because not every oncologist practices at a research hospital or has immediate access to the latest scientific discoveries.

Every year at the annual meeting of the American Society of Hematology (ASH), The Leukemia & Lymphoma Society sponsors a symposium in which investigators working on the newest advances in blood cancer research present their findings. The symposium is attended by more than 8,000 physicians and scientists in the field of hematology from all over the world.

In Fiscal Year 2002, the Society presented *Application of the New Biology to the Diagnosis and Treatment of the Hematologic Malignancies*. The program included information on new treatments for lymphoma and leukemia; the latest molecular diagnostic techniques for drug selection; the importance of proteomic methods for identifying critical targets for new drug development; and, drugs in the pipeline that act on specific molecular targets.

“I expanded our program to include both in-patients and out-patients, and the content is balanced. The first hour is educational and in the second, we deal with patient’s emotional needs.”

*Sandy Allen-Bard, NP, ANCC, OCN, Nurse Oncologist and Volunteer*

Ms. Allen-Bard is an Adult Nurse Practitioner at Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY
The Society is the world’s largest voluntary health organization dedicated to blood cancer research, education and patient services

Advancing our mission through the generosity of others

As a nonprofit, we rely on key members of our Society family — individuals, corporations, foundations and small- and medium-sized businesses — who serve the Society’s interests in diverse and ever-growing ways.

While economic circumstances imposed difficulties all around this year, our supporters rose to the occasion. Donors stood fast and even grew in numbers. Community support and spirit was unflaging.

■ Our fall Light The Night® Walk events across the country were scheduled during a time of national crisis following the tragic events of September 11. In many cases, re-scheduling or even cancellation was required. In spite of this, the Walks raised more dollars in Fiscal Year 2002 than in the prior year. This was accomplished with the assistance of community volunteers and the generous financial contributions and employee participation from Novartis, Verizon and others.

■ Team In Training® (TNT), the world’s largest endurance sports training program, faced similar challenges. When national air travel fell by 15 percent, our travel-dependent TNT program was kept from foundering by a quickly-implemented change in focus to events that were within driving distance of the majority of our TNT runners, walkers and cyclists.
“We like to do whatever we can to help. When we tell our friends and neighbors about the research the Society funds and how many people benefit from their services, most are happy to help.”

Dave & Cathy Swezey, Neighborhood Campaign Volunteers

“We created TNT in 1988 in honor of my daughter Georgia, who was diagnosed with ALL when she was two. Since that was the first year of TNT, we had nothing to follow except our instincts, and a strong desire to help the Society raise funds for blood cancer research.”

Bruce Cleland, Volunteer Fundraiser and Founder, Team In Training

The Society’s Team In Training is the world’s largest endurance sports training program that provides coaching and support for people to participate in marathons, cycling and triathlon events. It has raised $430 million since its inception.
Support for our cause came from people of all ages and every corner of the country. Toward the end of the year, multi-platinum recording artist Mandy Moore, the National Honorary Chairperson of our School & Youth Programs, visited Orange High School in Orange, CA, to celebrate the school’s status as the country’s highest School & Youth fundraisers. Students at this school raised more than $31,000.

We also relied on the efforts of our team of Celebrity Stars to help build awareness of and support for our causes. Cindy Crawford and Dan Jansen starred in public service announcements on the Society’s behalf.

All in all, the Society family pulled together when it counted most.

We would like to express our gratitude to the countless individuals, companies and other organizations who made our achievements possible this year — for their valuable time, financial support, services, employees and products along with their creativity and passion for curing blood cancers.

“Middle school kids can get so involved in their own issues that they fail to see the bigger picture. Part of my job is to help them see the value in doing something that benefits others. School & Youth makes that part of my job easier.”

Raniece Green, Special Education Teacher at Kenmoor Middle School in Landover, MD, with her eighth grade student, Alexandra Randolph
The Society’s vision to find cures for blood cancers is shared by many: the researchers who will unlock the cures, the donors who fund them, a national network of volunteers and the staff that supports their efforts.
I invest my time and money in the Society because I'm confident that my contributions will have a positive impact on the lives of people with blood cancer, and their families.

ALEXANDRA MAYES BIRNBAUM, MEMBER, NATIONAL BOARD OF TRUSTEES AND MAJOR DONOR

Our Visionaries See Hope in the Future

Research Grants

**Specialized Center of Research**

1. Jerry Adams, PhD - 2002
   Walter & Eliza Hall Institute of Medical Research
2. Irwin Bernstein, MD - 2003
   Fred Hutchinson Cancer Research Center
3. Selina Chen-Kiang, PhD - 2001
   Weill Medical College of Cornell University
4. Brian Druker, MD - 2001
   Oregon Health & Science University
5. James Griffin, MD - 2001
   Dana-Farber Cancer Institute
6. Stephen Nimer, MD - 2002
   Memorial Sloan-Kettering Cancer Center
7. Francisco Asturias, PhD - 2002
   Scripps Research Institute
8. Donald Ayer, PhD - 1999
   University of Utah School of Medicine
9. Ravi Basavappa, PhD - 2000
   University of Rochester
10. Timothy Behrens, MD - 1998
    University of Minnesota
11. Katherine Borden, PhD - 2001
    Mount Sinai School of Medicine
12. James Bowie, PhD - 2002
    University of California at Los Angeles
13. Emery Bresnick, PhD - 1998
    University of Wisconsin at Madison
    Harvard Medical School
15. Anthony Capobianco, PhD - 2002
    University of Cincinnati
16. J. Don Chen, PhD - 2001
    University of Massachusetts Medical School
17. Zhijian Chen, PhD - 2003
    University of Texas Southwestern Medical Center
18. Genhong Cheng, PhD - 2001
    University of California at Los Angeles
    Fox Chase Cancer Center
20. K.M. Coggeshall, PhD - 1999
    Oklahoma Medical Research Foundation
21. Pamela Correll, PhD - 2005
    Pennsylvania State University
22. Patricia Cortes, PhD - 2002
    Mount Sinai School of Medicine
23. Chris Counter, PhD - 2003
    Duke University Medical Center
    Children's Hospital at Los Angeles
25. George Daley, MD, PhD - 2000
    Whitehead Institute for Biomedical Research
26. James De Caprio, MD - 1998
    Dana-Farber Cancer Institute
27. James De Gregori, PhD - 2001
    University of Colorado Health Sciences Center
28. Michael Eck, MD, PhD - 2003
    Dana-Farber Cancer Institute
29. Laurence Eisenlohr, PhD - 2000
    Thomas Jefferson University
30. Mark Ewen, PhD - 1998
    Dana-Farber Cancer Institute
31. Susan Forsburg, PhD - 1998
    Salk Institute for Biological Studies
32. Alan Friedman, MD - 1999
    Johns Hopkins University School of Medicine
33. Xiang-Dong Fu, PhD - 1998
    University of California at San Diego
34. Margaret Goodell, PhD - 2002
    Baylor College of Medicine
35. Jonathan Graff, MD, PhD - 2002
    University of Texas Southwestern Medical Center
36. Michael Grushey, PhD - 1998
    Harvard School of Public Health
37. Wei Gu, PhD - 2002
    Columbia University
38. Anthony Imbalzano, PhD - 2000
    University of Massachusetts Medical School
39. Theodore Jardetzky, PhD - 2002
    Northwestern University
40. Dong-Yan Jin, MD, PhD - 2002
    University of Hong Kong
41. Jae Jung, PhD - 2001
    New England Regional Primate Research Center
42. Mark Kamps, PhD - 1998
    University of California at San Diego
43. William Kerr, PhD - 2003
    University of South Florida
44. Mark Ewen, PhD - 1998
    Dana-Farber Cancer Institute
45. James Burrows, MD - 1999
    Johns Hopkins University School of Medicine
46. Timothy Behrens, MD - 1998
    University of Minnesota
47. Katherine Borden, PhD - 2001
    Mount Sinai School of Medicine
48. James Bowie, PhD - 2002
    University of California at Los Angeles
49. Emery Bresnick, PhD - 1998
    University of Wisconsin at Madison
50. Stephen Buratowski, PhD - 2000
    Harvard Medical School
51. Anthony Capobianco, PhD - 2002
    University of Cincinnati
52. J. Don Chen, PhD - 2001
    University of Massachusetts Medical School
53. Zhijian Chen, PhD - 2003
    University of Texas Southwestern Medical Center
54. Genhong Cheng, PhD - 2001
    University of California at Los Angeles
55. Jonathan Chernoff, MD, PhD - 1998
    Fox Chase Cancer Center
56. K.M. Coggeshall, PhD - 1999
    Oklahoma Medical Research Foundation
57. Pamela Correll, PhD - 2005
    Pennsylvania State University
58. Patricia Cortes, PhD - 2002
    Mount Sinai School of Medicine
59. Chris Counter, PhD - 2003
    Duke University Medical Center
60. Gay Crooks, MB, BS - 2000
    Children's Hospital at Los Angeles
61. George Daley, MD, PhD - 2000
    Whitehead Institute for Biomedical Research
62. James De Caprio, MD - 1998
    Dana-Farber Cancer Institute
63. James De Gregori, PhD - 2001
    University of Colorado Health Sciences Center
64. Michael Eck, MD, PhD - 2003
    Dana-Farber Cancer Institute
65. Laurence Eisenlohr, PhD - 2000
    Thomas Jefferson University
66. Mark Ewen, PhD - 1998
    Dana-Farber Cancer Institute
67. Susan Forsburg, PhD - 1998
    Salk Institute for Biological Studies
68. Alan Friedman, MD - 1999
    Johns Hopkins University School of Medicine
69. Xiang-Dong Fu, PhD - 1998
    University of California at San Diego
70. Margaret Goodell, PhD - 2002
    Baylor College of Medicine
71. Jonathan Graff, MD, PhD - 2002
    University of Texas Southwestern Medical Center
72. Michael Grushey, PhD - 1998
    Harvard School of Public Health
73. Wei Gu, PhD - 2002
    Columbia University
74. Anthony Imbalzano, PhD - 2000
    University of Massachusetts Medical School
75. Theodore Jardetzky, PhD - 2002
    Northwestern University
76. Dong-Yan Jin, MD, PhD - 2002
    University of Hong Kong
77. Jae Jung, PhD - 2001
    New England Regional Primate Research Center
78. Mark Kamps, PhD - 1998
    University of California at San Diego
79. William Kerr, PhD - 2003
    University of South Florida
80. Mark Ewen, PhD - 1998
    Dana-Farber Cancer Institute
81. James Burrows, MD - 1999
    Johns Hopkins University School of Medicine
82. Timothy Behrens, MD - 1998
    University of Minnesota
83. Katherine Borden, PhD - 2001
    Mount Sinai School of Medicine
84. James Bowie, PhD - 2002
    University of California at Los Angeles
85. Emery Bresnick, PhD - 1998
    University of Wisconsin at Madison
86. Stephen Buratowski, PhD - 2000
    Harvard Medical School
87. Anthony Capobianco, PhD - 2002
    University of Cincinnati
88. J. Don Chen, PhD - 2001
    University of Massachusetts Medical School
89. Zhijian Chen, PhD - 2003
    University of Texas Southwestern Medical Center
90. Genhong Cheng, PhD - 2001
    University of California at Los Angeles
91. Jonathan Chernoff, MD, PhD - 1998
    Fox Chase Cancer Center
92. K.M. Coggeshall, PhD - 1999
    Oklahoma Medical Research Foundation
93. Pamela Correll, PhD - 2005
    Pennsylvania State University
94. Patricia Cortes, PhD - 2002
    Mount Sinai School of Medicine
95. Chris Counter, PhD - 2003
    Duke University Medical Center
96. Gay Crooks, MB, BS - 2000
    Children's Hospital at Los Angeles
97. George Daley, MD, PhD - 2000
    Whitehead Institute for Biomedical Research
98. James De Caprio, MD - 1998
    Dana-Farber Cancer Institute
99. James De Gregori, PhD - 2001
    University of Colorado Health Sciences Center
100. Michael Eck, MD, PhD - 2003
    Dana-Farber Cancer Institute
101. Laurence Eisenlohr, PhD - 2000
    Thomas Jefferson University
102. Mark Ewen, PhD - 1998
    Dana-Farber Cancer Institute
103. Susan Forsburg, PhD - 1998
    Salk Institute for Biological Studies
104. Alan Friedman, MD - 1999
    Johns Hopkins University School of Medicine
105. Xiang-Dong Fu, PhD - 1998
    University of California at San Diego
106. Margaret Goodell, PhD - 2002
    Baylor College of Medicine
107. Jonathan Graff, MD, PhD - 2002
    University of Texas Southwestern Medical Center
108. Michael Grushey, PhD - 1998
    Harvard School of Public Health
109. Wei Gu, PhD - 2002
    Columbia University
110. Anthony Imbalzano, PhD - 2000
    University of Massachusetts Medical School
111. Theodore Jardetzky, PhD - 2002
    Northwestern University
112. Dong-Yan Jin, MD, PhD - 2002
    University of Hong Kong
113. Jae Jung, PhD - 2001
    New England Regional Primate Research Center
114. Mark Kamps, PhD - 1998
    University of California at San Diego
115. William Kerr, PhD - 2003
    University of South Florida

1. The Specialized Center of Research Grant Program is funded in part by generous gifts from General Motors & Eli Lilly and Company.
2. The Specialized Center of Research Grant of Dr. Druker is funded in part by generous gifts to the Society from the Bertelsen Family, Cell Therapeutics, Inc. & the Miesel Foundation.
3. The Specialized Center of Research Grant of Dr. Nimer is funded in part by a generous gift to the Society from the John & Shirley Davies Foundation.
4. Dr. Bowie is funded in part by a generous gift to the Society from Parents Against Leukemia.
5. Dr. Crooks is funded in part by a generous gift to the Society from The Gail Cohen Leukemia Fund.
6. Dr. Daley, a Stephen Birnbaum Scholar, is funded by a generous gift to the Society from The Stephen Birnbaum Foundation.
7. Dr. Goodell, a Stephen Birnbaum Scholar, is funded by a generous gift to the Society from The Stephen Birnbaum Foundation.
8. Dr. Graff is funded by a generous gift to the Society from St. Valentine’s Day Luncheon & Style Show.
Nigel Killeen, PhD - 2001
University of California at San Francisco

Michael Kocz, PhD - 2000
Yale University School of Medicine

Anthony Koleske, PhD - 2003
Yale University

Sally Kornbluth, PhD - 1999
Duke University Medical Center

Kerry Kornfield, MD, PhD - 2002
Washington University School of Medicine

Stephen Kron, MD, PhD - 2003
University of Chicago

David Lambright, PhD - 1999
University of Massachusetts Medical School

Hyam Levitsky, MD - 1998
Johns Hopkins University School of Medicine

Daniel Lew, PhD - 2001
Duke University Medical Center

Paul Lieberman, PhD - 1998
Wistar Institute

Hsiun-Chi Liao, PhD - 2001
Well Medical College of Cornell University

Fenyourg Liu, PhD - 2002
University of California at Berkeley

Richard Longnecker, PhD - 1996
Northwestern University

Clifford Lowell, MD, PhD - 2002
University of California at San Francisco

Kun Ping Lu, MD, PhD - 1999
Beth Israel Deaconess Medical Center

Richard Mann, PhD - 1998
Columbia University

Andrews Matouschek, PhD - 2003
Northwestern University

Giuseppina Nucifora, PhD - 1999
University of Illinois at Chicago

Matthew O’Connell, PhD - 2001
Peter MacCallun Cancer Institute

Pier Pandolli, MD, PhD - 1998
Memorial Sloan-Kettering Cancer Center

Warren Pear, MD, PhD - 1999
University of Pennsylvania

David Pellman, MD - 2001
Dana-Farber Cancer Institute

Christoph Plass, PhD - 2005
Ohio State University

David Rawlings, MD - 2000
University of Washington

Ruibo Ren, MD, PhD - 1999
Brandeis University

Erle Robertson, PhD - 2000
University of Michigan Medical School

Moshe Sadowsky, MD, PhD - 2000
Albert Einstein College of Medicine of Yeshiva University

Kathleen Sakamoto, MD - 1999
University of California at Los Angeles

Guy Sauvageau, MD, PhD - 2005
Clinical Research Institute of Montreal

Mark Schlissel, MD, PhD - 1997
University of California at Berkeley

Edward Scott, PhD - 1999
University of Florida

David Selin, MD, PhD - 2001
Boston Medical Center

Ali Shirazi, PhD - 2002
St. Louis University School of Medicine

Ramesh Shivdasani, MD, PhD - 2001
Dana-Farber Cancer Institute

Gerald Sia, MD, PhD - 2001
Columbia University

Tomasz Skorski, MD, PhD - 2001
Temple University College of Sciences & Technology

Andreas Strasser, PhD - 1998
Walter & Eliza Hall Institute for Medical Research

Michel Streuli, PhD - 1998
Dana-Farber Cancer Institute

Charles Suk, PhD - 2000
Scripps Research Institute

Guillermo Taccioni, PhD - 1999
Boston University

Reshma Taneya, PhD - 2003
Mount Sinai School of Medicine

William Tansey, PhD - 2002
Cold Spring Harbor Laboratory

Dimitris Thanos, PhD - 2001
Columbia University

Michael Thirman, MD - 2003
University of Chicago

Sheila Thomas, PhD - 2000
Beth Israel Deaconess Medical Center

Toshio Tsukiyama, DVM - 2005
Fred Hutchinson Cancer Research Center

Richard Van Etten, MD, PhD - 1999
Center for Blood Research

David Van Vactor, PhD - 2001
Harvard Medical School

David Vaux, PhD - 2000
Walter & Eliza Hall Institute for Medical Research

Claire Walczak, PhD - 2002
Indiana University Medical Center

Jane Wu, PhD - 1999
Washington University

Kyojo Yokomori, PhD, DVM - 2001
University of California at Irvine

Faith Young, MD - 1999
University of Rochester

Dong-Er Zhang, PhD - 1999
Scripps Research Institute

Liang Zhu, MD, PhD - 2000
Albert Einstein College of Medicine of Yeshiva University

Yuan Zhuang, PhD - 1999
Duke University Medical Center

Career Development Program – Scholar in Clinical Research

Maurizio Bendandi, MD, PhD - 2002
Clinica Universitaria

Ravi Bhatia, MD - 2003
City of Hope National Medical Center

Smita Bhatia, MD - 2002
City of Hope National Medical Center

Robert Brousky, MD - 2001
Johns Hopkins Oncology Center

Richard Burt, MD - 1999
Northwestern University

John Byrd, MD - 2002
Ohio State University

Jorge Cortes, MD - 2001
University of Texas

Glenn Dranoff, MD - 2001
Dana-Farber Cancer Institute

Steven Gore, MD - 1999
Johns Hopkins University

Omer Koc, MD - 2002
Case Western Reserve University

Mary Laughlin, MD - 1999
Case Western Reserve University

Jane Liesveld, MD - 1999
University of Rochester Medical Center

Dana Matthews, MD - 2000
Fred Hutchinson Cancer Research Center

Nikhil Munshi, MD - 1999
Dana-Farber Cancer Institute

Owen O’Connor, MD, PhD - 1999
Dana-Farber Cancer Institute

Robert Soiffer, MD - 2000
Dana-Farber Cancer Institute

Wayne State University

Emory University

Christopher Walsh, MD, PhD - 2001
University of North Carolina at Chapel Hill

Ricardo Aguiar, MD, PhD - 2000
Dana-Farber Cancer Institute

Manzoor Ahmad, PhD - 2003
National Institute of Allergy & Infectious Disease

Paul Andreasen, PhD - 2002
Dana-Farber Cancer Institute

James Bear, PhD - 2002
Massachusetts Institute of Technology

Christopher Beh, PhD - 2000
University of California at Berkeley

Kamel Benlagha, PhD - 2003
Princeton University

Fred Bertrand, PhD - 2000
East Carolina University

Anja-Katrin Bielinsky, PhD - 2000
University of Minnesota

David Bilder, PhD - 2001
Harvard Medical School

Daniel Billadeau, PhD - 2000
Mayo Clinic & Foundation

Stacy Blain, PhD - 2000
Memorial Sloan-Kettering Cancer Center

Michael Boddly, PhD - 2001
Scripps Research Institute

Aleksey Bortvin, MD, PhD - 2000
Whitehead Institute for Biomedical Research

Ellen Cahill McFarland, PhD - 2002
Brigham & Women's Hospital

Fernando Casares, PhD - 2001
Universidade do Porto

Lucio Castilla, PhD - 2000
University of Massachusetts

Ching-Yi Chen, PhD - 2000
University of Alabama

9. Dr. Nucifora is funded in part by a generous gift to the Society from the Reichman Memorial & Altschul Foundation.

10. Dr. Pandolli is funded by a generous gift to the Society from the Brudnik Memorial & Altschul Foundation.

11. Dr. Sukamoto is funded by a generous gift to the Society from the Edward Fifer Estate.

12. Dr. Bhatia is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.

13. Dr. Byrd is funded by a generous gift to the Society from the Darcy Valentine Research Fund.

14. Dr. Matthews is funded in part by a generous gift to the Society from the Darcy Valentine Research Fund.

The Leukemia & Lymphoma Society
Andrei Kholkhatchev, PhD - 2000
Massachusetts General Hospital
Chang Kim, PhD - 2000 22
Stanford University
Tatiana Kolesnikova, PhD - 2000
Dana-Farber Cancer Institute
Rhett Kovall, PhD - 2001
Columbia University
Vashti Laclede, PhD - 2003
Stanford University
Matthew Lensch, PhD - 2003
Whitehead Institute for Biomedical Research
Anthony Letal, MD, PhD - 2002
Dana-Farber Cancer Institute
Jianze Li, PhD - 2000
Columbia University
Monika Liljedahl, MD, PhD - 2000
University of California at San Diego
Kao-I Lin, PhD - 2000
Columbia University
Meei-Yun Lin, PhD - 2001
University of California at San Diego
Jinli Liu, MD, PhD - 2000
Yale University School of Medicine
David Loeh, MD, PhD - 2001
Johns Hopkins University School of Medicine
Pei-Jung Lu, PhD - 2000
National Sun Yat-Sen University
Runqing Lu, PhD - 2002
University of Chicago
Biao Luo, PhD - 2000
Whitehead Institute for Biomedical Research
William Matsui, MD - 2002
Johns Hopkins University School of Medicine
Taha Merghoub, PhD - 2000
Memorial Sloan-Kettering Cancer Center
Golam Mohi, PhD - 2002
Beth Israel Deaconess Medical Center
Shivani Nautiyal, PhD - 2000
University of California at San Francisco
Erik Nelson, PhD - 2001
Dana-Farber Cancer Institute
Yael Nevo-Caspi, PhD - 2000
Tel Aviv University
Ramadevi Nimmanapalli, PhD - 2002
University of South Florida
Ichiko Nishijima, PhD - 2001
Baylor College of Medicine
Valerie Notenboom, PhD - 2002
Netherlands Cancer Institute
Claudia O'Shea, PhD - 2000
University of California at San Francisco
Koshi Oishi, MD, PhD - 2000
Fred Hutchinson Cancer Research Center
Paula Oliver, PhD - 2000
National Jewish Medical & Research Center
Kay Opperman, PhD - 2000
Johns Hopkins University
Cecile Pardoix, PhD - 2002
University of California at San Francisco
Toni Portis, PhD - 2000
Northwestern University Medical School
Natalie Prigozhina, PhD - 2003
Scripps Research Institute
Riley Prilliman, PhD - 2001
La Jolla Institute for Allergy & Immunology
Ling Qi, PhD - 2005
Johns Hopkins University
Christopher Raymond, PhD - 2003
Fred Hutchinson Cancer Research Center
Yvonne Reiss, PhD - 2002 25
Stanford University School of Medicine
Celeste Richardson, PhD - 2000 24
Harvard Medical School
Stephanie Rieder, PhD - 2000
Scripps Research Institute
Robert Rollins, PhD - 2002
Columbia University
Adam Rosenzweig, MD - 2003
Brigham & Women's Hospital
Karen Ross, PhD - 2002
National Institutes of Health
Hyung Ryoo, PhD - 2002
Rockefeller University
Shirksen Sacke, PhD - 2000
University of California at San Francisco
Joseph Scandura, MD, PhD - 2003
Memorial Sloan-Kettering Cancer Center
David Schwartz, PhD - 2003
Yale University
Neil Shah, MD, PhD - 2002 25
University of California at Los Angeles
Robert Sokollic, MD - 2001
Memorial Sloan-Kettering Cancer Center
Holger Sondermann, PhD - 2003
University of California at Berkeley
Christian Speck, PhD - 2002
Cold Spring Harbor Laboratory
Elizabeth Sprague, PhD - 2002
California Institute of Technology
Supriya Srinivasan, PhD - 2000
University of California at San Francisco
Elaine Storn, PhD - 1999
University of California at San Francisco
Jun Sun, PhD - 2002
Scripps Research Institute
Wayne Tam, MD, PhD - 2001
Weill Medical College of Cornell University
Vinay Tergauvkar, PhD - 2002
Salk Institute for Biological Studies
Scott Tibbets, PhD - 2001
Washington University
Susheela Tridandapani, PhD - 2001
Ohio State University
Indira Unnikrishnan, PhD - 2000
Tufts University School of Medicine
Pablo Wappner, PhD - 1998
Camponar Institute
Ann Welch, PhD - 2001
American Red Cross
Markus Welcker, PhD - 2002
Fred Hutchinson Cancer Research Center
Julie Wilson-Annan, PhD - 2000
Walter & Eliza Hall Institute for Medical Research
Jingsong Xu, PhD - 2003
University of California at San Francisco
Dong Yu, PhD - 2001
Princeton University
Katherine Zahradka, PhD - 2002
Mount Sinai School of Medicine
Chengcheng Zhang, PhD - 2002
Whitehead Institute for Biomedical Research
Fungyi Zhao, PhD - 2003
University of Minnesota

Translational Research Program

Vahid Afsar-Kharghan, MD - 2003 26
Baylor College of Medicine
Ricardo Aguiar, MD, PhD - 2002
Dana-Farber Cancer Institute
Denis Alexander, PhD - 2003
Babraham Institute
Robert Arceci, MD, PhD - 1998
Johns Hopkins University School of Medicine
David Avigan, MD - 2002
Beth Israel Deaconess Medical Center
Maria Baer, MD - 2003
Roswell Park Cancer Institute

22. Dr. Banker is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
23. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
24. Bruce Richardson, the GlassNeuralKillerismototee B. Ellen Fellow of The Leukemia & Lymphoma Society, is funded by a generous endowment from GlassNeuralKillerismototee B. Ellen and the GlassNeuralKillerismototee B. Ellen Foundation.
25. Dr. Shah is funded by a generous gift to the Society from the Mary D. Ahearn Memorial Research Fund.
26. Dr. Afsar-Kharghan is funded by a generous gift from the Shylykhaiaost Division in partnership with The Leukemia & Lymphoma Society.
27. Dr. Banker is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.
28. Dr. Cheng is funded in part by a generous gift to the Society from Lincsiia Retti for C.J. McKinnis.
29. Dr. Afshar-Kharghan is funded by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
30. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
31. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
32. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
33. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
34. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
35. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
36. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
37. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
38. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
39. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
40. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
41. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
42. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
43. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
44. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
45. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
46. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
47. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
48. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
49. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
50. Dr. Kolesnikova is funded in part by a generous gift to the Society from Delora Sanfilippo in memory of Hank Morine & Bob Stauffer.
Medical and Scientific Advisors

Kenneth C. Anderson, MD  
Dana-Farber Cancer Institute

Ellin Berman, MD  
Memorial Sloan-Kettering Cancer Center

David M. Bodine, PhD  
NHGRI/Hematopoiesis Section  
National Institutes of Health

Jonathan Braun, MD, PhD  
Chair  
UCLA Medical Center

Paul Calabresi, MD  
Brown University School of Medicine

Michael Caligiuri, MD  
The Ohio State University

Curt Cuvin, MD  
Johns Hopkins Comprehensive Cancer Center

Alan D. D'Andrea, MD  
Department of Pediatric Oncology  
Dana-Farber Cancer Institute

Brian Druker, MD  
Hematology/Medical Oncology  
Oregon Health Sciences University

Stephen G. Emerson, MD, PhD  
Chief  
Hematology/Oncology  
University of Pennsylvania

Alan M. Gewirtz, MD, Chair  
Medicine and Pathology  
University of Pennsylvania School of Medicine

James D. Griffin, MD  
Vice Chair for Research  
Professor of Medicine  
Dana-Farber Cancer Institute

Armand Keating, MD  
Princess Margaret Hospital

Beverly S. Mitchell, MD, Vice Chair  
Lineberger Comprehensive Cancer Center  
University North Carolina Medical Center

Steven T. Rosen, MD  
Robert H. Lurie Comprehensive Cancer Center

Owen N. Witte, MD  
Howard Hughes Medical Institute

Richard J. O'Reilly, MD  
Chairman  
Department of Pediatrics  
Memorial Sloan Kettering Cancer Center

Joel Rappaport, MD  
Department of Internal Medicine  
Yale School of Medicine

David G. Poplack, MD  
Elise C. Young  
Department of Pediatrics  
Hematology-Oncology Section  
Baylor College of Medicine

Naomi Rosenberg, PhD  
Tufts University School of Medicine

Margaret A. Shipp, MD  
Dana-Farber Cancer Institute

Cheryl L. Willman, MD  
Department of Pathology  
University of New Mexico Cancer Center

Leona Samson, PhD - 1999  
Massachusetts Institute of Technology

Daniela Santoli, PhD - 1999  
Wistar Institute

Mathias Schmid, MD - 2001  
University Hospital of Ulm, Germany

Joachim Schultze, MD - 2000  
Dana-Farber Cancer Institute

Stephen Schuster, MD - 2002  
University of Pennsylvania

Oliver Semmes, PhD - 2003  
Eastern Virginia Medical School

Mathias Schmid, MD - 2001  
University of Utah School of Medicine

Margaret Shipp, MD - 2001  
Dana-Farber Cancer Institute

Judith Shizuru, MD, PhD - 2003  
Stanford University

Nelson Teng, MD, PhD - 1998  
Stanford University

Helen Tighe, PhD - 2000  
University of California at San Diego

Michael Tomasson, MD - 2003  
Washington University School of Medicine

Marcel van den Brink, MD, PhD - 2001  
Memorial Sloan-Kettering Cancer Center

Frits van Bhee, MD, PhD - 2001  
University of Arkansas for Medical Sciences

Andrea Velardi, MD - 2002  
Università di Perugia

Catherine Verfaillie, MD - 1997  
University of Minnesota

Regis Vilchez, MD - 2005  
Baylor College of Medicine

Ellen Vittetta, PhD - 2001  
University of Texas

Edmund Waller, MD, PhD - 1998 / 2002  
Emory University

Christopher Walsh, MD, PhD - 1996  
University of North Carolina at Chapel Hill

Paul Weiden, MD - 2001  
Virginia Mason Research Center

Brice Weinberg, MD - 2001  
Duke University Medical Center

Peter Wiernik, MD - 1999  
Our Lady of Mercy Medical Center

Qing Yi, MD, PhD - 2000 / 2003  
University of Arkansas for Medical Sciences

James Young, MD - 1999  
Memorial Sloan-Kettering Cancer Center

Alice Yu, MD, PhD - 1999 / 2002  
University of California at San Diego

35. Dr. Tighe is funded by a generous gift to the Society from the Chuck Griffin Memorial Research Program.

36. Dr. van Bhee is funded by a generous gift to the Society from the Jim Jacobs Charitable Foundation & the Jim Jacobs Endowment Research Fund.

37. Dr. Vittetta is funded by a generous gift to the Society from St. Valentine’s Day Luncheon & Style Show.

38. Dr. Weinberg is funded by a generous donation from the Jim Jacobs Charitable Foundation & the Jim Jacobs Endowment Research Fund.

39. Dr. Yi is funded by a generous gift to the Society from the Kim King Multiple Myeloma Research Fund.

40. Dr. Yu is funded in part by a generous gift to the Society from the Jacqueline O’Rourke & David Gonzalez families.
## Sponsor and Promotion Partnerships

### Sponsorships

Institutions or individuals that support a Society event.

#### $100,000 – $499,999

- American Bicycle Association
- Charities Automobile Recycling Enterprises, LLC dba WeCARE
- Cub Foods
- The Edward Filer Estate
- Verizon
- Volvo Cars of North America, LLC
- Windward Homes

#### $50,000 – $99,999

- Anchor Bancorp, Inc.
- Bank of America
- Catherine B. Reynolds Foundation
- Corixa/GlaxoSmithKline
- DARcARS
- Genentech, Inc.
- Madison Dearborn Partners, Inc.
- Michael McCarthy Foundation
- Novartis Pharmaceuticals Corporation
- Rudy Project
- Sweet ’N Low/Cumberland Packing Corp.
- The Sallie Mae Fund
- Washington Area Chrysler Plymouth Jeep Dealers Advertising Association, Inc.
- Washington Area New Automobile Dealers Association
- Wyeth-Ayerst Pharmaceuticals

#### $10,000 – $49,999

- A&P
- Accenture
- Aether Systems
- Agency.com, Ltd.
- AHL Services, Inc.
- Akin, Gump, Strauss, Kauer & Feld, LLP
- Alaska Airlines
- Alcade & Fay
- Allfirst Bank
- Alliance Steel
- Alpha Medica
- Amanten Fund
- American Airlines
- American Investors
- Anchorage Daily News
- Andersen, LLP
- Anheuser-Busch Companies
- Anning-Johnson Company
- Anon Consulting
- Arnold & Porter
- AT&T
- AT&T Foundation
- Aventis Pharmaceuticals
- Bank of America
- Bank of Louisville Charities
- Bank One N.A. & Bank One Capital Markets, Inc.
- Baseline Middle School
- Baxter
- Baxter Health Care Company
- Beechwood Company
- Deborah Bennett
- Bennett, Turner & Coleman, LLP
- Berlex Oncology
- Bert Smith & Co.
- BlueCross BlueShield of Mississippi
- BlueCross BlueShield of California
- Bowne & Co., Inc.
- BP Amoco
- Bristol Myers Squibb
- Buck Consultants
- C.J. Coakley Co., Inc.
- California-Nevada Operating Engineers
- Campbell & Company
- Capital One
- Carella, Byrne, Gilfillan, Cecchi, Stewart & Olestein
- Gary Cary
- Cecil & Irene Hylton Foundation
- Celgene Corporation
- Cell Therapeutics, Inc.
- Chick-fil-A
- Children of Maryanne & Henry J. Knott, Jr.
- Children’s Charities
- Cingular
- Citigroup Foundation
- Clark/Bardes, Inc.
- Cleary, Gottlieb, Steen & Hamilton
- Citibank, Inc.
- Cliper Navigation
- Comcast
- Philip S. Contacos
- Corporate Express Business Interiors
- Costco
- Credit Suisse/First Boston Corporation
- Crimi Mae Management, Inc.
- David M. Crowley, Jr.
- Cruise Industry Charitable Foundation
- Cumberland Packing Corp./Sweet ’N Low
- Daimler Chrysler Corporation
- Daimler Chrysler
- Danaher Foundation
- Deloitte & Touche
- Deloitte Consulting
- Denny Hacker’s Auto Connection
- Deutsche Bank
- Dewey Ballantine, LLP
- Di Pasquale Enterprises Subway
- Doctors+ Designers
- John & Leslie Dorman
- Dow Chemical
- Dresser Industries
- EFW, Inc.
- ELG Haniel Metals Corp.
- Enterprise Rent-A-Car Foundation
- Enterprise Roofing Services, Inc.
- Enterprise Solutions Group
- Ernst & Young, LLP
- Mr. & Mrs. David B. Falk
- Fannie Mae
- Fannie Mae Foundation
- Fidelity National Title
- First Union Bank
- Ford Credit
- Freddie Mac Foundation
- Freedom Capital Management Corporation
- Steve A. Feld
- Fred O. Funkhouser
- General Electric Plastics
- General Motors Corporation
- Gibson Musical Instruments
- Gilis Thomas Company
- GIP, Inc.
- GMAC
- Goldman, Sachs & Co.
- Haemonetics
- Heartfelt Hands Therapeutic Massage
- Heller Financial
- Hershey Park Arena and Hockey Club
- Hewlett Packard
- High Five Foundation
- Laura Hirschmann
- Hitachi
- HITT Contracting, Inc.
- Holiday Stationstores
- Horizon BlueCross BlueShield of New Jersey
- Human Genome Sciences, Inc.

---

“T’ve supported the Society since the early 90’s, when I lost my father-in-law to leukemia. Working with my company to form Team Verizon for Light The Night, we set high fundraising goals which we’ve happily exceeded.”

Ed Beckley, Volunteer Fundraiser

---

Team Verizon is the Society’s largest Light The Night team, raising over $450,000 in 2002, from Verizon employees across the country, their friends and families and the company’s foundation.
<table>
<thead>
<tr>
<th>Company/Group</th>
<th>Donor Level</th>
<th>City/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hunt &amp; Walsh, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDEC Pharmaceuticals Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMC, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Innovative Communications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International House of Pancakes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrity Healthcare Services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J. Ira &amp; Nicki Harris Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J.D. Salthouse Associates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JMorgan Chase and Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>James L. Eichberg Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan M. &amp; Eugenia Krol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charitable Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JFK Medical Center</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JNS Consulting Engineers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Jordan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamionka Entertainment Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K-Designer's</td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Kellenyi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peter R. &amp; Cynthia K. Kellogg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ken &amp; Linda Lay Family Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kerr Drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key Bank</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kirkland &amp; Ellis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knights of Columbus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KPMG Consulting, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KPMG, LLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LaSalle Bank</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCM Associates, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lehman Brothers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruth Lewis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linebarger, Goggan, Blair, Pens &amp; Sampson, LLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Litho Partners</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunardis Markets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Luth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mackenzie Partners, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manugistics, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marsh USA, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masonite International Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massey Charitable Trust</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBNA Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCG Capital Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McGuire &amp; Sons Plumbing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Office Properties, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MedImmune, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memorial Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercer Human Resource Consulting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merrill Lynch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGW Group, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miami Heat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mickey Rutman</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mid-America Bank of America</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milgard Windows</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan Stanley &amp; Co, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mount Gay Rum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Murray Recreation Association, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Commerical Flooring &amp; Design Solutions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Rural Utilities Cooperative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Orleans Saints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northrop Grumman Information Technology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northwestern Mutual Financial Network</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NVR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oracle Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ortho Biotech Products, L.P.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oscar Printing Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paley Rothman</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parmalat-USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pat Gallagher, PGT Trucking, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paycor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paymontech, L.P.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEPCO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PepsiCo Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PepsiCo, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peter &amp; Georgia Angelos Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Industry's Fight Against Leukemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Golf Outing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phi Gamma Delta</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philip Morris Companies, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phoenix Suns</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PhRMA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piper Marbury Rudnick &amp; Wolfe, LLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plumbers &amp; Pipeliners Local Union 72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNC Bank</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prairie Meadows Racetrack &amp; Casino</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price Modern, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PricewaterhouseCoopers, LLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro-Cuts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein Design Labs, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prudential Financial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Putnam Investments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality Food Centers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radigan &amp; Radigan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bags for Riches</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhein Family Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhode Island Lifespan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert E. Toray &amp; Co., Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocky Mountain Boatworks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ross Laboratories/Abbott International</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salomon Smith Barney Members of Citigroup</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sam's Club</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scheer Partners, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schering Plough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schroeder Investment Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sea Watch International, Ltd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silver Star Casino &amp; Resort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skyy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slumberland Furniture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sonny's Real-Pit Bar-B-Q</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sony Digital Audio Disc Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sprint</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sprint PCS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stanley E. Brown Family Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STE-DEL Services, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SunTrust</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SunTrust Bank</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supercaligirious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suzuki Motor Corp.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synergyex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syracuse Hematology/Oncology, P.C.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tarrant Partners, L.P.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Team Foot Works</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenet Louisiana Healthsystem</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Breeden-Adams Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The C. Kenneth &amp; Laura Baxter Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Chili Society, Ltd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Edward Fifer Estate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Leonsis Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Mills Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Moorsings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Niello Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Ralph H. &amp; Ruth J. McCullough Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Torrey Companies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Videre Group, LLP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tidewater Glazing, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travelers Express</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Truland Service Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tully's Coffee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turner Construction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Bank and First American Funds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ULLICO Management Co.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Association</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPMC Health Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>USB/Paine Webber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verizon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verizon Wireless</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginia Oncology Association</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginia Sprinkler Company, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vought Aircraft Industries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warners’ Stellian</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wartsila</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Washington Gas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Watson Wyatt Worldwide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WEJ5 Charities Fund of Robert R.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCormick Tribune Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weschler/Marisco Association</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West Marine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Will Hoover Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Williams Organizational Partnerships, El Paso</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilmer, Cutler &amp; Pickering</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Womens Council HBASI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow Corporation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Promotions**

*Institutions or individuals that organize an event and donate proceeds to the Society.*

<table>
<thead>
<tr>
<th>Donor Level</th>
<th>City/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,000,000 and above</td>
<td></td>
</tr>
<tr>
<td>Dial America Marketing, Inc.</td>
<td></td>
</tr>
<tr>
<td>$500,000 – $999,999</td>
<td></td>
</tr>
<tr>
<td>KGO NewsTalk AM810</td>
<td></td>
</tr>
<tr>
<td>$100,000 – $499,999</td>
<td></td>
</tr>
<tr>
<td>JPMorgan Chase and Company</td>
<td></td>
</tr>
<tr>
<td>Rbhaba Jones</td>
<td></td>
</tr>
<tr>
<td>Sunflower Opera Company</td>
<td></td>
</tr>
<tr>
<td>WYAY-FM Eagle 106.7</td>
<td></td>
</tr>
<tr>
<td>$50,000 – $99,999</td>
<td></td>
</tr>
<tr>
<td>The Patriot News</td>
<td></td>
</tr>
<tr>
<td>WFBQ Radio – The Bob &amp; Tom Show</td>
<td></td>
</tr>
<tr>
<td>$10,000 – $49,999</td>
<td></td>
</tr>
<tr>
<td>“Racing for a Reason”</td>
<td></td>
</tr>
<tr>
<td>1053 WIMZ-Knoxville, TN</td>
<td></td>
</tr>
<tr>
<td>Adelphia Cable</td>
<td></td>
</tr>
<tr>
<td>Albritton, abc27</td>
<td></td>
</tr>
<tr>
<td>Azo, Inc.</td>
<td></td>
</tr>
<tr>
<td>Bank of America</td>
<td></td>
</tr>
<tr>
<td>Baseline Middle School</td>
<td></td>
</tr>
<tr>
<td>Don &amp; Sally Cameron</td>
<td></td>
</tr>
<tr>
<td>Gary Cary</td>
<td></td>
</tr>
<tr>
<td>Clear Channel Broadcasting Stations</td>
<td></td>
</tr>
<tr>
<td>Cohutta Water</td>
<td></td>
</tr>
<tr>
<td>Comcast Cable</td>
<td></td>
</tr>
<tr>
<td>Comcast-Knoxville, TN</td>
<td></td>
</tr>
<tr>
<td>Community Health Charities of Alabama, Inc.</td>
<td></td>
</tr>
<tr>
<td>Donald &amp; Sherry Eden</td>
<td></td>
</tr>
<tr>
<td>Ernst &amp; Young</td>
<td></td>
</tr>
<tr>
<td>Evernham Motorsports</td>
<td></td>
</tr>
<tr>
<td>Fox 13 – Memphis, TN</td>
<td></td>
</tr>
<tr>
<td>H.G. Hill Food Stores</td>
<td></td>
</tr>
<tr>
<td>Hendrick BMW</td>
<td></td>
</tr>
<tr>
<td>IDEC Pharmaceuticals Corporation</td>
<td></td>
</tr>
<tr>
<td>Infinity Broadcasting Corp.</td>
<td></td>
</tr>
<tr>
<td>Joseph Rosi Jewelers</td>
<td></td>
</tr>
<tr>
<td>JMorgan Chase and Company</td>
<td></td>
</tr>
<tr>
<td>Kerr Drugs</td>
<td></td>
</tr>
<tr>
<td>Ladd Hanford Chrysler-Plymouth</td>
<td></td>
</tr>
<tr>
<td>Dodge-Jeep-Manda</td>
<td></td>
</tr>
</tbody>
</table>
The Legacy Circle
The Legacy Circle honors those who have included the Society in an estate plan.

Hugh Albora
Peter Alexas
Bruce Allen
Fay Allen
Mr. & Mrs. David Andrews
James & Eileen Andrews
Mr. & Mrs. Jay Barrows
Claudia & Stephen Barto, Jr.
Dennis Beardsley
Ami Berkowitz
Alexandra Mayes Birnbaum
The Stephen Birnbaum Foundation
Margaret Black
Christopher Blum *
Lori Blum
Sally Blume
Robert H. & Janet Bohannon
James Bolton
William Boyd
Wilburn Brewer, Jr.
Richard Cahill
Mary Carver
Betty Chalmers
Robert Charon
Pasquale R. Cheche
Thomas Cheek
Sylvia Clemetson
Paul and Nancy Clendening
Michelle Cromwell
Katherine Wagner & Cook
Anthony Cortese, MD
Marianne Cotter
Raymond Cox
Marilyn J. Crohan
Edmund D’Allesio
Dr. & Mrs. Michael L. Dean
Carolyn Dee
David & Connie Dimling
Kathy Direckx
Joel Drake
Harry & Barbara Dunlap
Agnes Dury
J. Stephen Eckert
Greg Elfers
Mr. & Mrs. Jeffrey Ellena
Lynne E. Fazzi
Richard A. Fess
Harold Fennell
Harvey Fernbach, MD
Helen F. Fisher
Mr. & Mrs. James T. Fox
David Frantze
Paul N. Frimmer
Betsy Garrigan
John A. Goshgarian
Richard & Jacqueline Geswell
Noreen L. Giese
Heather Girard
Wade Goehring
Richard Goldberg
Wilma Gottlieb
Rebecca Ann Grajewska
Ruth Granat
Mr. & Mrs. Forrest Grosvenor
Dan & Donna Gubits
Mr. & Mrs. Ken Haller
Keith P. Harendza
Alice Hatch
Pat Hauer
Kathleen Hays, RN, MSN
Tom & Wendy Henry
Catherine E. Hildreth
C. Brooks Hoffman
Larry Hostetler
Beth Hoth
Jeanie Hoover *
Lynn Hoover
Roy Hovinen
Dwayne Howell
Heather Hunt
William Ianniello
Joan Jarrett
Anne K. Johnson
Harry & Donna Johnson III
Nathan & Ruthie T. Katz
Michael Kerper
Frances Keating
T. Corry Kipp
Monica Klapper
Karl Koeppke
Jeff & Teresa Kopitz
Carmella Kramer
Leslie E. Krause
Mr. & Mrs. Greg Kulm
Janet LaVere
John Lamb, Jr.
William S. Lear
Diana Lynn Lee
Gail M. Lee
Paul L. Lewis
Geoffrey Lombard
Mr. & Mrs. F.F. Michael Lynch
Ida Malena
Dr. & Mrs. Stanley N. Marks
Greg Martin
William Martin
Mark E. Mason
Joan Maves
John & Patty McDonald
Thomas & Olive McDonald
Dorothy McCann
Sylvia McGovern
Carolyn E. McKown
Joshua Mitchell, MD
Ted Mocian
Michael & Tammy Moloy
Dennis F. Moore, MD
Joan Moran
Mr. & Mrs. Thaddee F. Moreau
Dennis Morris
Frank Munro
Suzanne J. Muntzing
Rodman N. Myers
Robert J. Myers
The Honorable Robert H. Newman
Robert C. Niles
Edward Nofield III
Jason North
Richard F. Nourie
Carolyn & Jerry O’Hara
Edward D. O’Malley
Mrs. Harry O’Toole
Margaret Olmazou
George Omiros
Rosemary Ophrook
Mary J. Oyer
Jacqueline Anne Palmenberg
Mr. and Mrs. Paul Pulsch
Stephen M. Peters
Leslea S. Pidgeon
William Pike
George Pooley
Larry Pyles
David R. & Toni Quinty
Marty Rauch
Richard & Kathy Reader
James Reelink
David Rice *
Marilyn Richardson
Ernest Rüse
Selena Rogers
Seth & Carolyn Rudnick
Kevin R. Ryan
Delora Sanfilippo
Karl Schaetzer
Lucy Schonbrun
Lorraine Seidel
Frank T. Short
Norbert J. Sieber
Jay and Elaine Silver
Tena Simmons
Irene Skomro
Mary-Gail Smith
Mr. & Mrs. Robert Smith
Russell D. Smith
Nicoma Sobolewski
John C. Sorrell
Elda Spano
James E. Sparkes
Barbara A. Spiegel
Thomas & Joanne Spink
Mark & Carol Spisak
Paula & Phillip Stone
Marcie Summerlin
Patricia Trosclair
Heather Turnball
Joseph Verdrame, MD
Beverly G. Warner
Philip F. Warner
Mr. & Mrs. Robin Wallach
John E. Walter
Paul Weiden, MD
Vicki Weland
Deborah Weinstein
Paul & Annie Weiss
Mr. & Mrs. John Wenpe
Dr. & Mrs. Stanley A. White
Don Wier
Mr. & Mrs. Douglas Young
Katherine Zell-Cherry
Anonymous (101)

* Deceased

Members as of June 30, 2002

The Legacy Circle honors those who have included the Society in an estate plan.
Independent Auditors’ Report

Board of Trustees
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2002, and the related statements of activities, cash flows, and functional expenses for the year then ended. These consolidated financial statements are the responsibility of the Society’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Society’s 2001 consolidated financial statements and, in our report dated October 5, 2001, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2002, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

KPMG LLP

October 10, 2002
New York, NY
## Consolidated Statement of Financial Position

*The Leukemia & Lymphoma Society, Inc.*  
June 30, 2002  
(with comparative amounts at June 30, 2001)  
(in thousands)

### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 9,628</td>
<td>$ 7,933</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>849</td>
<td>1,135</td>
</tr>
<tr>
<td>Legacies and contributions receivable (note 2)</td>
<td>4,440</td>
<td>4,153</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>3,537</td>
<td>2,475</td>
</tr>
<tr>
<td>Investments, at fair value (note 3)</td>
<td>72,194</td>
<td>74,282</td>
</tr>
<tr>
<td>Equipment and leasehold improvements, less accumulated depreciation and amortization of $4,071 and $2,357</td>
<td>4,457</td>
<td>4,449</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$ 95,105</strong></td>
<td><strong>$ 94,427</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

#### Liabilities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$ 11,348</td>
<td>$ 9,861</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>4,654</td>
<td>3,474</td>
</tr>
<tr>
<td>Grants payable (note 4)</td>
<td>40,261</td>
<td>38,584</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>56,263</strong></td>
<td><strong>51,919</strong></td>
</tr>
</tbody>
</table>

#### Net assets:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>34,903</td>
<td>38,489</td>
</tr>
<tr>
<td>Temporarily restricted (note 7)</td>
<td>2,819</td>
<td>2,929</td>
</tr>
<tr>
<td>Permanently restricted (note 7)</td>
<td>1,120</td>
<td>1,090</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>38,842</strong></td>
<td><strong>42,508</strong></td>
</tr>
</tbody>
</table>

### Total liabilities and net assets                                           | **$ 95,105** | **$ 94,427** |

*See accompanying notes to consolidated financial statements.*
# Consolidated Statement of Activities

*The Leukemia & Lymphoma Society, Inc.*  
*Year ended June 30, 2002*  
*(with summarized totals for the year ended June 30, 2001)*  
*(in thousands)*

## Revenue

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total 2002</th>
<th>Total 2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>172,542</td>
<td></td>
<td></td>
<td>174,286</td>
<td>178,136</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(27,747)</td>
<td></td>
<td></td>
<td>(27,747)</td>
<td>(31,287)</td>
</tr>
<tr>
<td><strong>Net campaign contributions</strong></td>
<td>144,795</td>
<td></td>
<td></td>
<td>146,539</td>
<td>146,849</td>
</tr>
<tr>
<td>Legacies</td>
<td>4,206</td>
<td></td>
<td></td>
<td>4,206</td>
<td>2,550</td>
</tr>
<tr>
<td>Net interest and dividend income (note 3)</td>
<td>2,010</td>
<td></td>
<td></td>
<td>2,063</td>
<td>2,965</td>
</tr>
<tr>
<td>Net decrease in fair value of investments</td>
<td>(2,819)</td>
<td></td>
<td></td>
<td>(2,907)</td>
<td>(2,990)</td>
</tr>
<tr>
<td>Grant refunds</td>
<td>1,607</td>
<td></td>
<td></td>
<td>1,607</td>
<td>1,052</td>
</tr>
<tr>
<td><strong>Net assets released from restrictions</strong></td>
<td>1,789</td>
<td></td>
<td></td>
<td>1,789</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>151,588</td>
<td>(110)</td>
<td>30</td>
<td>151,508</td>
<td>150,426</td>
</tr>
</tbody>
</table>

## Expenses (note 8)

**Program Services:**

- Research                                      | 39,172       |                        |                        | 39,172        | 37,700        |
- Patient and community service                   | 41,843       |                        |                        | 41,843        | 42,368        |
- Public health education                         | 28,554       |                        |                        | 28,554        | 26,195        |
- Professional education                          | 7,306        |                        |                        | 7,306         | 7,083         |
- **Total program services**                      | 116,875      |                        |                        | 116,875       | 113,346       |

**Supporting Services:**

- Management and general                          | 10,573       |                        |                        | 10,573        | 10,151        |
- Fund raising                                    | 27,726       |                        |                        | 27,726        | 26,108        |
- **Total supporting services**                   | 38,299       |                        |                        | 38,299        | 36,259        |

**Total expenses**                                | 155,174      |                        |                        | 155,174       | 149,605       |

**Change in net assets**                          | (5,586)      | (110)                  | 30                     | (3,666)       | 821           |

## Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>38,489</td>
<td>42,508</td>
</tr>
<tr>
<td><strong>End of year</strong></td>
<td>$34,903</td>
<td>$42,508</td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
Consolidated Statement of Cash Flows  
The Leukemia & Lymphoma Society, Inc.  
Year ended June 30, 2002  
(with comparative amounts for the year ended June 30, 2001)  
(in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>(3,666)</td>
<td>821</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net decrease in fair value of investments</td>
<td>2,907</td>
<td>2,990</td>
</tr>
<tr>
<td>Permanently restricted campaign contributions</td>
<td>(30)</td>
<td>(29)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>1,714</td>
<td>1,217</td>
</tr>
<tr>
<td>Changes in assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease (increase) in accounts receivable</td>
<td>286</td>
<td>(101)</td>
</tr>
<tr>
<td>Increase in legacies and contributions receivable</td>
<td>(287)</td>
<td>(1,555)</td>
</tr>
<tr>
<td>Increase in prepaid expenses</td>
<td>(1,062)</td>
<td>(55)</td>
</tr>
<tr>
<td>Increase in accounts payable and accrued expenses</td>
<td>1,487</td>
<td>2,219</td>
</tr>
<tr>
<td>Increase in deferred revenue</td>
<td>1,180</td>
<td>61</td>
</tr>
<tr>
<td>Increase in grants payable</td>
<td>1,677</td>
<td>4,328</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>4,206</td>
<td>9,896</td>
</tr>
</tbody>
</table>

| **CASH FLOWS FROM INVESTING ACTIVITIES:** |          |          |
| Purchases of equipment and leasehold improvements | (1,722)  | (3,188)  |
| Purchases of investments, net | (819)    | (9,918)  |
| Net cash used in investing activities | (2,541)  | (13,106) |

| **CASH FLOWS FROM FINANCING ACTIVITIES:** |          |          |
| Permanently restricted campaign contributions | 30       | 29       |
| Net cash provided by financing activities | 30       | 29       |

Net increase (decrease) in cash and cash equivalents | 1,695 | (5,181) |
Cash and cash equivalents at beginning of year | 7,935 | 11,114 |
Cash and cash equivalents at end of year | **$ 9,628** | **$ 7,935** |

See accompanying notes to consolidated financial statements.
Consolidated Statement of Functional Expenses
The Leukemia & Lymphoma Society, Inc.
Year ended June 30, 2002
(with comparative totals for the year ended June 30, 2001)
(in thousands)

<table>
<thead>
<tr>
<th></th>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Total</th>
<th>Direct donor benefit costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Research</td>
<td>Management</td>
<td>Fundraising</td>
<td>Total</td>
</tr>
<tr>
<td>Awards and grants</td>
<td>$37,648</td>
<td>$376,48</td>
<td>$36,106</td>
<td>$37,648</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salaries</td>
<td>468</td>
<td>4081</td>
<td>3,405</td>
<td>39,802</td>
</tr>
<tr>
<td>Employee benefits and taxes</td>
<td></td>
<td></td>
<td></td>
<td>36,244</td>
</tr>
<tr>
<td>Occupancy (note 6)</td>
<td>19</td>
<td>583</td>
<td>927</td>
<td>5,399</td>
</tr>
<tr>
<td>Insurance</td>
<td>6</td>
<td>38</td>
<td>99</td>
<td>412</td>
</tr>
<tr>
<td>Telephone</td>
<td>16</td>
<td>251</td>
<td>1,069</td>
<td>3,280</td>
</tr>
<tr>
<td>Travel</td>
<td>25</td>
<td>229</td>
<td>378</td>
<td>2,141</td>
</tr>
<tr>
<td>Printing and supplies</td>
<td>170</td>
<td>1,798</td>
<td>6,698</td>
<td>20,963</td>
</tr>
<tr>
<td>Equipment rentals and maint.</td>
<td>7</td>
<td>178</td>
<td>289</td>
<td>1,646</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>57</td>
<td>547</td>
<td>3,870</td>
<td>10,338</td>
</tr>
<tr>
<td>Meetings</td>
<td>228</td>
<td>245</td>
<td>397</td>
<td>2,894</td>
</tr>
<tr>
<td>Professional fees and contract services</td>
<td>417</td>
<td>1,479</td>
<td>5,314</td>
<td>15,780</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>11</td>
<td>90</td>
<td>135</td>
<td>828</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>23</td>
<td>162</td>
<td>401</td>
<td>2,849</td>
</tr>
<tr>
<td>Total expenses</td>
<td>$39,172</td>
<td>$10,573</td>
<td>$155,174</td>
<td>$15,747</td>
</tr>
</tbody>
</table>

Program Services: 75.3%
Supporting Services: 24.7%
Research 25.2%
Patient and Community Service 27.0%
Public Health Education 18.4%
Professional Education 4.7%
Management and General 6.8%
Fundraising 17.9%

See accompanying notes to consolidated financial statements.
Notes to Consolidated Financial Statements  
The Leukemia & Lymphoma Society, Inc.  
June 30, 2002  
(with comparative amounts as of and for the 
year ended June 30, 2001)

1. Organization and Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (the “Society”) is a national not-for-profit health agency dedicated to seeking the cause and eventual cure of leukemia, lymphoma, Hodgkin’s disease and myeloma and improving the quality of life of patients and their families. The Society’s principal activities, which are conducted through its local chapters and the Home Office, include: awarding research grants; facilitating psychosocial support groups; providing financial aid to patients; answering phone requests for blood-related cancer information made to the Society’s Information Resource Center; and disseminating educational information about blood-related cancers in the form of publications, internet sites and symposia sponsorship for both the medical community and the general public.

Tax-Exempt Status
The Society qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since the Society is publicly-supported, contributions to the Society qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Society, which encompasses the Home Office of the Society and its fifty-nine chapters, as well as its not-for-profit affiliates, Leukemia Society Research Programs, Inc. and Leukemia Society of America Research Foundation. All significant inter-company and intra-Society accounts and transactions have been eliminated in consolidation.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to the Society, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of the Board of Trustees, for the Society to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period or purpose, as well as amounts relating to term endowment or deferred giving arrangements in which the funds must be maintained intact over the lifetimes of the donors.

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity and that only the income be used. Income earned on these funds may be unrestricted or temporarily restricted, depending upon the donor-imposed restrictions.

Contributions and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Temporarily restricted contributions that are received and expended in the same period are reported as unrestricted contributions. Conditional contributions are recognized as revenue when the conditions have been substantially met.

Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

Donated Services
A substantial number of volunteers have made significant contributions of their time to help develop the Society’s programs and activities. The value of such volunteer services has not been reflected in the accompanying consolidated financial statements as it does not meet the criteria for revenue recognition.

Cash Equivalents
Cash equivalents consist of money market accounts and short-term investments with a maturity of three months or less from date of purchase, except for amounts held for long-term purposes reported as investments.

Equipment, Leasehold Improvements and Depreciation
Equipment and leasehold improvements are recorded at cost, if purchased, or at fair value at date of donation, if donated. Equipment and leasehold are depreciated using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter.

Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires the Society’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Summarized Financial Information
The financial statements are presented with 2001 comparative information. With respect to the statement of activities, such prior year information is not presented by net assets class and, in the statement of functional expenses, 2001 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with the Society’s 2001 financial statements from which the summarized information was derived.
2. Legacies and Contributions Receivable

The Society's legacies and contributions receivable at June 30, 2002 and 2001 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$3,649</td>
<td>$3,103</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>600</td>
<td>900</td>
</tr>
<tr>
<td>After 5 years</td>
<td>333</td>
<td>333</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>4,582</strong></td>
<td><strong>4,336</strong></td>
</tr>
</tbody>
</table>

Less discount to present value:

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>(discount rate - 5%)</td>
<td>(142)</td>
<td>(183)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$4,440</strong></td>
<td><strong>$4,153</strong></td>
</tr>
</tbody>
</table>

3. Investments

The following is a summary of investments at June 30, 2002 and 2001 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds</td>
<td>$25,341</td>
<td>$25,341</td>
</tr>
<tr>
<td>Corporate notes and bonds</td>
<td>2,7518</td>
<td>2,7876</td>
</tr>
<tr>
<td>Common stocks and mutual funds</td>
<td>21,357</td>
<td>18,580</td>
</tr>
<tr>
<td>U.S. Government obligations</td>
<td>403</td>
<td>339</td>
</tr>
<tr>
<td>Other</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$74,677</strong></td>
<td><strong>$72,194</strong></td>
</tr>
</tbody>
</table>

Debt and equity securities are recorded at fair value as determined by quoted market prices. Mutual funds are recorded at fair value using published unit values. Investment expenses of $305,000 and $261,000 have been netted against interest and dividend income for the years ended June 30, 2002 and 2001, respectively.

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by the Society's Board of Trustees. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of the Society's Board of Trustees. In addition to unconditional grants payable of $40,261,000 at June 30, 2002, the Society has grant commitments of $63,476,000 that are conditioned upon future events and, accordingly, are not recorded.

5. Pension Plan

The Society has a noncontributory, defined contribution 401(k) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expense under this plan aggregated $1,644,000 and $1,530,000 for the years ended June 30, 2002 and 2001, respectively.

6. Occupancy Expense and Lease Commitments

The leases for premises which the Society's Home Office and chapters occupy expire on various dates through January 15, 2011 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses and utilities.

The approximate minimum future annual rental commitments are summarized as follows (in thousands):

Year ended June 30:

<table>
<thead>
<tr>
<th></th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$4,654</td>
<td>$4,492</td>
<td>$4,040</td>
<td>$3,360</td>
<td>$2,550</td>
<td>6,050</td>
<td><strong>$25,146</strong></td>
</tr>
</tbody>
</table>

7. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets were available for the following purposes at June 30, 2002 and 2001 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research program</td>
<td>$1,640</td>
<td>$1,074</td>
<td>$2,010</td>
<td>$1,046</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient service and bone marrow donor programs</td>
<td>350</td>
<td>-</td>
<td>292</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional education program</td>
<td>50</td>
<td>46</td>
<td>51</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other programs</td>
<td>779</td>
<td>-</td>
<td>576</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$2,819</strong></td>
<td><strong>$1,120</strong></td>
<td><strong>$2,929</strong></td>
<td><strong>$1,090</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8. Joint Costs Allocation

In 2002 and 2001, the Society incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$11,986</td>
<td>$11,407</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,262</td>
<td>1,608</td>
</tr>
<tr>
<td>Public health education</td>
<td>8,060</td>
<td>5,488</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$21,308</strong></td>
<td><strong>$18,505</strong></td>
</tr>
</tbody>
</table>
### National Leaders

#### Chairman of the Board
- Norbert J. Sieber
  - Executive Vice President
  - MARC USA
  - Pittsburgh, PA

#### Vice Chairman
- Frank T. Short
  - Government Services Director
  - Leagre Chandler and Millard LLP
  - Indianapolis, IN

#### Vice Chairman for Medical and Scientific Affairs
- Alan M. Gewirtz, MD
  - Stem Cell Biology & Therapeutic Program
  - University of Pennsylvania Cancer Center
  - Philadelphia, PA

#### Secretary/Treasurer
- Donald H. Salsberg
  - Director of Finance
  - UFCW
  - Washington, DC

#### National Board of Trustees

<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fay Allen</td>
<td>Jeffersonville, IN</td>
</tr>
<tr>
<td>Irwin D. Bernstein, MD</td>
<td>Program Head, Pediatric Oncology Program</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center</td>
<td></td>
</tr>
<tr>
<td>Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>Alexandra Mayes Birnbaum</td>
<td>New York, NY</td>
</tr>
<tr>
<td>M. O. Breeding</td>
<td>Oklahoma City, OK</td>
</tr>
<tr>
<td>Paul Calabresi, MD, MACP</td>
<td>Professor of Medicine &amp; Medical Science and Chairman Emeritus, Department of Medicine</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center</td>
<td></td>
</tr>
<tr>
<td>Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>Kathryn L. Calame, PhD</td>
<td>Department of Microbiology</td>
</tr>
<tr>
<td>College of Physicians and Surgeons</td>
<td></td>
</tr>
<tr>
<td>Columbia University</td>
<td></td>
</tr>
<tr>
<td>New York, NY</td>
<td></td>
</tr>
<tr>
<td>Robert A. “Spider” Cantley</td>
<td>Fremont, CA</td>
</tr>
<tr>
<td>Thomas Chappel</td>
<td>Director of Safety, Health and Disability Management</td>
</tr>
<tr>
<td>Alabama Power Foundation, Inc.</td>
<td></td>
</tr>
<tr>
<td>Birmingham, AL</td>
<td></td>
</tr>
<tr>
<td>John M. Collin, PhD</td>
<td>Professor of Microbiology</td>
</tr>
<tr>
<td>Tufts University School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Michael Copley</td>
<td>Community Liaison</td>
</tr>
<tr>
<td>Children's Hospital &amp; Health Center</td>
<td></td>
</tr>
<tr>
<td>San Diego, CA</td>
<td></td>
</tr>
<tr>
<td>Raymond Cox</td>
<td>President</td>
</tr>
<tr>
<td>Elite Beverages</td>
<td></td>
</tr>
<tr>
<td>Indianapolis, IN</td>
<td></td>
</tr>
<tr>
<td>David Denihan</td>
<td>Marsh, Inc.</td>
</tr>
<tr>
<td>Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>Bruce Douglass</td>
<td>Boulder, CO</td>
</tr>
<tr>
<td>Cynthia M. Driscoll</td>
<td>Director</td>
</tr>
<tr>
<td>Women &amp; Infants Hospital of Rhode Island</td>
<td></td>
</tr>
<tr>
<td>Providence, RI</td>
<td></td>
</tr>
<tr>
<td>Brian Drucker, MD</td>
<td>Dw of Hematology/Medical Oncology</td>
</tr>
<tr>
<td>Oregon Health Sciences University</td>
<td></td>
</tr>
<tr>
<td>Portland, OR</td>
<td></td>
</tr>
<tr>
<td>Lawrence D. Ellis, MD</td>
<td>Professor of Medicine</td>
</tr>
<tr>
<td>University of Pittsburgh</td>
<td></td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>Stephen G. Emerson, MD, PhD</td>
<td>Chief, Hematology-Oncology</td>
</tr>
<tr>
<td>University of Pennsylvania School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>Richard A. Fess</td>
<td>President</td>
</tr>
<tr>
<td>Mid-Florida Agencies of Orlando, Inc.</td>
<td></td>
</tr>
<tr>
<td>Longwood, FL</td>
<td></td>
</tr>
<tr>
<td>Richard C. Ficken</td>
<td>Eden Prairie, MN</td>
</tr>
<tr>
<td>Thomas L. Fitzpatrick</td>
<td>Manager of Corporate Credit</td>
</tr>
<tr>
<td>Saint Gobain Corporation</td>
<td></td>
</tr>
<tr>
<td>Worcester, MA</td>
<td></td>
</tr>
<tr>
<td>Frances M. Fox, RN, MSN</td>
<td>President</td>
</tr>
<tr>
<td>Home Instead Senior Care</td>
<td></td>
</tr>
<tr>
<td>Mt. Laurel, NJ</td>
<td></td>
</tr>
<tr>
<td>David Frantze</td>
<td>Stinson, Mag &amp; Fizzell, PC</td>
</tr>
<tr>
<td>Kansas City, MO</td>
<td></td>
</tr>
<tr>
<td>Christine K. Frisbee</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Richard Garrison</td>
<td>President and Owner</td>
</tr>
<tr>
<td>Advertising Novelty Co., Inc.</td>
<td></td>
</tr>
<tr>
<td>Washington, DC</td>
<td></td>
</tr>
<tr>
<td>John A. Geoghegan</td>
<td>Gellert and Quartararo Purchase, NY</td>
</tr>
<tr>
<td>Paul G. Glaab</td>
<td>Glaab &amp; Associates, Inc.</td>
</tr>
<tr>
<td>Laguna Niguel, CA</td>
<td></td>
</tr>
<tr>
<td>Susan Ann J. Glass</td>
<td>Richmond, VA</td>
</tr>
<tr>
<td>James D. Griffin, MD</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Carter K. Guice, Jr.</td>
<td>Mandeville, LA</td>
</tr>
<tr>
<td>Keith P. Harenda</td>
<td>President/Owner</td>
</tr>
<tr>
<td>KPH Construction Corp.</td>
<td></td>
</tr>
<tr>
<td>Milwaukee, WI</td>
<td></td>
</tr>
<tr>
<td>Kathleen Hays, RN, MN</td>
<td>Director, Inpatient Oncology Services</td>
</tr>
<tr>
<td>University of Pittsburgh Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>Patrick J. Healy, PhD</td>
<td>Senior Vice President for Finance and Administration</td>
</tr>
<tr>
<td>Quinnipiac University</td>
<td></td>
</tr>
<tr>
<td>Hamden, CT</td>
<td></td>
</tr>
<tr>
<td>Gary D. Hirsch</td>
<td>Chairman</td>
</tr>
<tr>
<td>Elk Capital, LLC</td>
<td></td>
</tr>
<tr>
<td>Rye, NY</td>
<td></td>
</tr>
<tr>
<td>Lynn C. Hoover</td>
<td>Stinson Morison Hecker LLP</td>
</tr>
<tr>
<td>Kansas City, MO</td>
<td></td>
</tr>
<tr>
<td>Thomas F. Hunter</td>
<td>President &amp; CEO</td>
</tr>
<tr>
<td>Spar Performance Group</td>
<td></td>
</tr>
<tr>
<td>Carrollton, TX</td>
<td></td>
</tr>
<tr>
<td>William Ianniello</td>
<td>President</td>
</tr>
<tr>
<td>Professional Painting, Inc.</td>
<td></td>
</tr>
<tr>
<td>New Haven, CT</td>
<td></td>
</tr>
<tr>
<td>Dan J. Jordanger</td>
<td>Partner</td>
</tr>
<tr>
<td>Hunton &amp; Williams</td>
<td>Richmond, VA</td>
</tr>
<tr>
<td>John M. Kamins</td>
<td>Partner</td>
</tr>
<tr>
<td>Honigman Miller Schwartz and Cohn</td>
<td>Detroit, MI</td>
</tr>
<tr>
<td>Judith E. Karp, MD</td>
<td>Professor of Medicine</td>
</tr>
<tr>
<td>Greenebaum Cancer Center</td>
<td></td>
</tr>
<tr>
<td>University of Maryland Medical Systems</td>
<td></td>
</tr>
<tr>
<td>Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>Michael Keating, MD</td>
<td>M.D. Anderson Cancer Center</td>
</tr>
<tr>
<td>Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Leslie Elliot Krause, Esq.</td>
<td>Law Offices of Leslie Elliot Krause</td>
</tr>
<tr>
<td>New York, NY</td>
<td></td>
</tr>
<tr>
<td>Marie Lauria, MSW</td>
<td>Clinical Associate Professor</td>
</tr>
<tr>
<td>University of North Carolina</td>
<td></td>
</tr>
<tr>
<td>Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>William S. Lear</td>
<td>Director</td>
</tr>
<tr>
<td>Potter Group</td>
<td></td>
</tr>
<tr>
<td>Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>Diana Lee</td>
<td>Wichita, KS</td>
</tr>
<tr>
<td>Lynn M. Lesko, MD, PhD</td>
<td>Senior Associate Director</td>
</tr>
<tr>
<td>International Clinical Research</td>
<td></td>
</tr>
<tr>
<td>General Medicine Division</td>
<td></td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Ridgefield, CT</td>
<td></td>
</tr>
<tr>
<td>Michael W. Long, PhD</td>
<td>Professor, Department of Pediatrics</td>
</tr>
<tr>
<td>Member, Comprehensive Cancer Center</td>
<td></td>
</tr>
<tr>
<td>University of Michigan Medical Center</td>
<td></td>
</tr>
<tr>
<td>Ann Arbor, MI</td>
<td></td>
</tr>
<tr>
<td>Mark E. Mason</td>
<td>Vice Chairman</td>
</tr>
<tr>
<td>Oxford Development Company</td>
<td></td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>Catherine M. Mattson</td>
<td>Marketing Development Manager</td>
</tr>
<tr>
<td>Hewlett Packard</td>
<td></td>
</tr>
<tr>
<td>Roseville, CA</td>
<td></td>
</tr>
<tr>
<td>W. Stratford May, Jr., MD, PhD</td>
<td>Director</td>
</tr>
<tr>
<td>Shands Cancer Center, University of Florida</td>
<td></td>
</tr>
<tr>
<td>Gainesville, FL</td>
<td></td>
</tr>
<tr>
<td>Thomas R. McDonald</td>
<td>Marana, AZ</td>
</tr>
<tr>
<td>Carolyn E. Mckown</td>
<td>Felton, DE</td>
</tr>
<tr>
<td>L. Wright Moody</td>
<td>Deloitte &amp; Touche</td>
</tr>
<tr>
<td>Dennis F. Moore, MD, FACP</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>Community Liaison</td>
<td></td>
</tr>
<tr>
<td>Children's Hospital &amp; Health Center</td>
<td></td>
</tr>
<tr>
<td>Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Virginia S. Morris</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Suzanne J. Muntzing</td>
<td>Wealth Management Specialist</td>
</tr>
<tr>
<td>Wells Fargo</td>
<td></td>
</tr>
<tr>
<td>Walnut Creek, CA</td>
<td></td>
</tr>
<tr>
<td>Rodman N. Myers</td>
<td>Of Counsel</td>
</tr>
<tr>
<td>Honigman Miller Schwartz and Cohn</td>
<td>Detroit, MI</td>
</tr>
<tr>
<td>Deborah R. Nix</td>
<td>Dalzell, SC</td>
</tr>
<tr>
<td>Andrew E. Nolan</td>
<td>Partner</td>
</tr>
<tr>
<td>PricewaterhouseCoopers LLP</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>Jason North</td>
<td>JSN Consulting</td>
</tr>
<tr>
<td>Palm Beach, FL</td>
<td></td>
</tr>
<tr>
<td>Mary J. Oyer</td>
<td>Northfield, IL</td>
</tr>
<tr>
<td>Frederic C. Parvey</td>
<td>Director</td>
</tr>
<tr>
<td>Alltel</td>
<td></td>
</tr>
<tr>
<td>Jacksonville, FL</td>
<td></td>
</tr>
<tr>
<td>David G. Poplack, MD</td>
<td>Director</td>
</tr>
<tr>
<td>Texas Children's Cancer Center</td>
<td></td>
</tr>
<tr>
<td>Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Peter J. Quesenberry</td>
<td>Chair, Department of Research</td>
</tr>
<tr>
<td>Roger Williams Medical Center</td>
<td>Providence, RI</td>
</tr>
<tr>
<td>Fordham University, PA</td>
<td></td>
</tr>
</tbody>
</table>

---

38
The Leukemia & Lymphoma Society Research Foundation

Officers

Harry Pearce, President
Chairman, Hughes Electronics Corporation

Norbert J. Sieber, Vice President
Executive Vice President, MARC USA; Chairman, The Leukemia & Lymphoma Society

Alan M. Gewirtz, MD,
Medical Vice President
Professor of Medicine & Pathology, University of Pennsylvania Cancer Center; Vice Chairman for Medical and Scientific Affairs, The Leukemia & Lymphoma Society

Dwayne Howell, Secretary-Treasurer
President & Chief Executive Officer, The Leukemia & Lymphoma Society

Medical Advisory Board

Edward J. Benz, Jr., MD
President, Dana-Farber Cancer Institute

Donald Pinkel, MD
Chairman, Institutional Review Board Driscoll Children's Hospital

Louis W. Sullivan, MD
President, Morehouse School of Medicine

E. Donnall Thomas, MD
Member, Fred Hutchinson Cancer Research Center; Professor of Medicine, Emeritus University of Washington School of Medicine

Senior Staff

Dwayne Howell
President & CEO

Field & Human Resources Development

Cynthia Gardner Cross
Executive Vice President Field & Human Resources Development

Paul Weiss
Senior Vice President Field Development

Finance, Administration & Information Technology

John Walter
Executive Vice President & Chief Financial Officer

Finance, Administration & Information Technology

Jimmy Nangle
Vice President & Controller

Finance

Stephen B. Lucas
Chief Information Officer

Government & Legislative Affairs

George Dahlman
Vice President, Public Policy

Marketing Communications & Revenue Development

Richard J. Geswell
Executive Vice President

Marketing & Revenue Development

Nancy Klein
Senior Vice President

Marketing Communications

Greg Ellers
Senior Vice President

Campaign Development

Michael F. Aldrich
Vice President

Marketing & Product Development

Geralyn LaNeve
Vice President

Communications

The Leukemia & Lymphoma Society

Dwayne Howell
President & CEO

Field & Human Resources Development

Cynthia Gardner Cross
Executive Vice President Field & Human Resources Development

Paul Weiss
Senior Vice President Field Development

Finance, Administration & Information Technology

John Walter
Executive Vice President & Chief Financial Officer

Finance, Administration & Information Technology

Jimmy Nangle
Vice President & Controller

Finance

Stephen B. Lucas
Chief Information Officer

Government & Legislative Affairs

George Dahlman
Vice President, Public Policy

Marketing Communications & Revenue Development

Richard J. Geswell
Executive Vice President

Marketing & Revenue Development

Nancy Klein
Senior Vice President

Marketing Communications

Greg Ellers
Senior Vice President

Campaign Development

Michael F. Aldrich
Vice President

Marketing & Product Development

Geralyn LaNeve
Vice President

Communications

The Leukemia & Lymphoma Society Research Foundation

Officers

Harry Pearce, President
Chairman, Hughes Electronics Corporation

Norbert J. Sieber, Vice President
Executive Vice President, MARC USA; Chairman, The Leukemia & Lymphoma Society

Alan M. Gewirtz, MD,
Medical Vice President
Professor of Medicine & Pathology, University of Pennsylvania Cancer Center; Vice Chairman for Medical and Scientific Affairs, The Leukemia & Lymphoma Society

Dwayne Howell, Secretary-Treasurer
President & Chief Executive Officer, The Leukemia & Lymphoma Society

Medical Advisory Board

Edward J. Benz, Jr., MD
President, Dana-Farber Cancer Institute

Donald Pinkel, MD
Chairman, Institutional Review Board Driscoll Children's Hospital

Louis W. Sullivan, MD
President, Morehouse School of Medicine

E. Donnall Thomas, MD
Member, Fred Hutchinson Cancer Research Center; Professor of Medicine, Emeritus University of Washington School of Medicine

Senior Staff

Dwayne Howell
President & CEO

Field & Human Resources Development

Cynthia Gardner Cross
Executive Vice President Field & Human Resources Development

Paul Weiss
Senior Vice President Field Development

Finance, Administration & Information Technology

John Walter
Executive Vice President & Chief Financial Officer

Finance, Administration & Information Technology

Jimmy Nangle
Vice President & Controller

Finance

Stephen B. Lucas
Chief Information Officer

Government & Legislative Affairs

George Dahlman
Vice President, Public Policy

Marketing Communications & Revenue Development

Richard J. Geswell
Executive Vice President

Marketing & Revenue Development

Nancy Klein
Senior Vice President

Marketing Communications

Greg Ellers
Senior Vice President

Campaign Development

Michael F. Aldrich
Vice President

Marketing & Product Development

Geralyn LaNeve
Vice President

Communications

The Leukemia & Lymphoma Society

Dwayne Howell
President & CEO

Field & Human Resources Development

Cynthia Gardner Cross
Executive Vice President Field & Human Resources Development

Paul Weiss
Senior Vice President Field Development

Finance, Administration & Information Technology

John Walter
Executive Vice President & Chief Financial Officer

Finance, Administration & Information Technology

Jimmy Nangle
Vice President & Controller

Finance

Stephen B. Lucas
Chief Information Officer

Government & Legislative Affairs

George Dahlman
Vice President, Public Policy

Marketing Communications & Revenue Development

Richard J. Geswell
Executive Vice President

Marketing & Revenue Development

Nancy Klein
Senior Vice President

Marketing Communications

Greg Ellers
Senior Vice President

Campaign Development

Michael F. Aldrich
Vice President

Marketing & Product Development

Geralyn LaNeve
Vice President

Communications
Chapter Offices (alphabetical by state)

Alabama
Alabama Chapter
100 Chase Park South, Suite 220
Birmingham, AL 35244
Phone: (205) 989-0098

Arizona
Desert Mountain States Chapter
2990 E. Northern Avenue, E-100
Phoenix, AZ 85028
Phone: (602) 788-8622

California
Greater Los Angeles Chapter
6033 West Century Blvd., Suite 300
Los Angeles, CA 90045
Phone: (310) 216-7600

Greater San Francisco Bay Area Chapter
1390 Market Street, Suite 1200
San Francisco, CA 94102-5306
Phone: (415) 625-1100

Greater Sacramento Area Chapter
3103 Folsom Circle, Suite 101
Sacramento, CA 95827
Phone: (916) 369-7581

San Diego/Hawaii Chapter
8575 Gibbs Drive, Suite 262
San Diego, CA 92125
Phone: (619) 277-1800

Silicon Valley/Monterey Bay Area Chapter
675 North First Street, Suite 1100
San Jose, CA 95112-5135
Phone: (408) 271-2875

Tri-County Chapter
233 N. Broadway, Suite 320
Santa Ana, CA 92706
Phone: (714) 881-0610

Colorado
Rocky Mountain Chapter
5335 W. Dartmouth Avenue
Denver, CO 80227
Phone: (303) 984-2110

Connecticut
Connecticut Chapter
300 Research Parkway, Suite 310
Meriden, CT 06450
Phone: (203) 379-0445

Fairfield County CT Chapter
25 Third Street, 4th Floor
Stamford, CT 06905
Phone: (203) 967-8326

Delaware
Delaware Chapter
100 West 10th Street, Suite 209
Wilmington, DE 19801
Phone: (302) 661-7300

District of Columbia
National Capital Area Chapter
5845 Richmond Highway
Suite 630
Alexandria, VA 22305
Phone: (703) 960-1100

Florida
Central Florida Chapter
3310 Maguire Blvd., Suite 101
Orlando, FL 32803
Phone: (407) 898-0733

Northern Florida Chapter
9145 Phillips Highway
Suite 130, Exchange South
Jacksonville, FL 32256
Phone: (904) 338-6211

Palm Beach Area Chapter
4560 Northlake Boulevard, Suite 109
Palm Beach Gardens, FL 33410
Phone: (561) 775-9954

Southern Florida Chapter
3325 Hollywood Boulevard, Suite 400
Hollywood, FL 33021
Phone: (954) 961-3244

Kentucky
Kentucky Chapter
710 West Main Street, Suite 201
Louisville, KY 40202-2600
Phone: (502) 584-8490

Louisiana
Louisiana Chapter
3636 South Faison Street
Suite 304
Metairie, LA 70001
Phone: (504) 857-9495

Maryland
Maryland Chapter
8600 LaSalle Road
Chester Building, Suite 314
Baltimore, MD 21286-2011
Phone: (410) 625-1960

Massachusetts
Massachusetts Chapter
495 Old Connecticut Path
Suite 220
Framingham, MA 01701
Phone: (508) 879-5065

Michigan
Michigan Chapter
1421 E. Twelve Mile Road, Bldg. A
Madison Heights, MI 48071
Phone: (248) 582-2900

Minnesota
Minnesota Chapter
5217 Wayzata Blvd., Suite 221
St. Louis Park, MN 55416
Phone: (952) 345-3309

Mississippi
Mississippi Chapter
405 Fontaine Place, Suite 103
Ridgeland, MS 36915
Phone: (601) 956-7474

Missouri
The Gateway Chapter
77 West Port Plaza, Suite 101
St. Louis, MO 63146-3111
Phone: (314) 678-0780

Nebraska
Nebraska Chapter
2665 Farmarn Street
Omaha, NE 68131
Phone: (402) 544-2202

New Jersey
New Jersey Chapter
45 Springfield Avenue
Springfield, NJ 07081
Phone: (973) 376-9539

New York
New York Chapter
3613 N.W. 56th Street, Suite 230
Miami, FL 33127-1370
Phone: (305) 248-5606

Ohio
Ohio Chapter
3105 Fite Circle, Suite 101
Louisville, KY 40202-2690
Phone: (502) 584-8490

Pennsylvania
Pennsylvania Chapter
6135 Fairview Road, Suite 250
Charlotte, NC 28210
Phone: (704) 988-5012

Rhode Island
Rhode Island Chapter
5410 Newport Road, Suite 205
Providence, RI 02906
Phone: (401) 734-8888

South Carolina
South Carolina Chapter
1247 Lake Murray Boulevard
Irmo, SC 29063
Phone: (803) 721-4299

Southern Ohio Chapter
105 West Fourth Street, Suite 900
Cincinnati, OH 45202
Phone: (513) 361-2100

Southern New Jersey/South Shore Chapter
216 Haddon Avenue, Suite 328
Westmont, NJ 08108
Phone: (856) 692-0200

Texas
North Texas Chapter
12850 Spurling Drive, Suite 220
Dallas, TX 75230
Phone: (972) 273-0959

Tennessee
Tennessee Chapter
464 Metroplex Drive, Suite A-200
Nashville, TN 37211-3139
Phone: (615) 331-2980

Utah
South/West Texas Chapter
12850 Spurling Drive, Suite 220
Dallas, TX 75230
Phone: (972) 273-0959

Virginia
Virginia Chapter
2101 Executive Drive, Tower Box 21
Hampton, VA 23666
Phone: (757) 836-3511

Washington
Washington/Alaska Chapter
530 Dexter Avenue N., Suite 300
Seattle, WA 98109
Phone: (206) 935-4572

Wisconsin
Wisconsin Chapter
4125 N. 14th Street, Unit A
Brookfield, WI 53005
Phone: (262) 970-4701
The journey of hope begins with you

The Leukemia & Lymphoma Society counts on the generosity of individuals, companies, foundations and other organizations to help us find cures and improve the quality of life for patients and families. Donations may comprise money, time, talent and products or services.

When individuals are able to make a significant donation, there are many options. Examples are cash or appreciated securities, or inclusion of the Society in a will, trust, insurance policy or other estate planning vehicle. These donors are honored with membership in the de Villiers Society.* Those who make a future gift through their estate plans are also recognized in our Legacy Circle.

Please join our Journey of Hope. For more information about how you can help the Society prolong, enhance and save the lives of people with blood cancers, contact us toll free at 888.773.9958.

Thank you.

* The de Villers Society is named for our founders, who created the Society in 1949 after losing a child to leukemia.

The Society is a 501(c)3 organization.